Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2248845,steady state plasma concentration,Atracurium was infused for the first 1 h to maintain a target steady state plasma concentration of 1.0 microgram ml-1.,Pharmacokinetics of atracurium during continuous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248845/),[μg] / [ml],1.0,1378,DB00732,Atracurium besylate
,2248845,clearances,"The clearances of atracurium, estimated by the constant infusion rate required to maintain the steady state plasma concentration, at 50-60 min and during estimation of Cpss90 were 3.8 (1.0) and 3.9 (1.1) ml kg-1 min-1 (ns), respectively.",Pharmacokinetics of atracurium during continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248845/),[ml] / [kg·min],3.8,1379,DB00732,Atracurium besylate
,2248845,Cpss90,"The clearances of atracurium, estimated by the constant infusion rate required to maintain the steady state plasma concentration, at 50-60 min and during estimation of Cpss90 were 3.8 (1.0) and 3.9 (1.1) ml kg-1 min-1 (ns), respectively.",Pharmacokinetics of atracurium during continuous infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248845/),[ml] / [kg·min],3.8,1380,DB00732,Atracurium besylate
,2248845,Cpss90,"The clearances of atracurium, estimated by the constant infusion rate required to maintain the steady state plasma concentration, at 50-60 min and during estimation of Cpss90 were 3.8 (1.0) and 3.9 (1.1) ml kg-1 min-1 (ns), respectively.",Pharmacokinetics of atracurium during continuous infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248845/),[ml] / [kg·min],3.9,1381,DB00732,Atracurium besylate
,2248845,volume of distribution at steady state,"The volume of distribution at steady state of atracurium after 1 h of infusion, calculated using the clearance and the area under the plasma concentration-time curve to 1 h, was 130 (50) ml kg-1.",Pharmacokinetics of atracurium during continuous infusion. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248845/),[ml] / [kg],130,1382,DB00732,Atracurium besylate
,2248845,area under the plasma concentration-time curve to 1 h,"The volume of distribution at steady state of atracurium after 1 h of infusion, calculated using the clearance and the area under the plasma concentration-time curve to 1 h, was 130 (50) ml kg-1.",Pharmacokinetics of atracurium during continuous infusion. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248845/),[ml] / [kg],130,1383,DB00732,Atracurium besylate
,3778789,volume of distribution (area),"There were no significant differences in volume of distribution (area) (139 v. 152 ml kg-1), clearance (5.1 v. 5.3 ml kg-1 min-1), T1/2 alpha (2.1 v. 2.0 min), or T1/2 beta (19.1 v. 20.3 min) between children with normal hepatic and renal function and those with moderately impaired hepatic function presenting for hepatic transplantation.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),[ml] / [kg],139,1595,DB00732,Atracurium besylate
,3778789,volume of distribution (area),"There were no significant differences in volume of distribution (area) (139 v. 152 ml kg-1), clearance (5.1 v. 5.3 ml kg-1 min-1), T1/2 alpha (2.1 v. 2.0 min), or T1/2 beta (19.1 v. 20.3 min) between children with normal hepatic and renal function and those with moderately impaired hepatic function presenting for hepatic transplantation.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),[ml] / [kg],152,1596,DB00732,Atracurium besylate
,3778789,clearance,"There were no significant differences in volume of distribution (area) (139 v. 152 ml kg-1), clearance (5.1 v. 5.3 ml kg-1 min-1), T1/2 alpha (2.1 v. 2.0 min), or T1/2 beta (19.1 v. 20.3 min) between children with normal hepatic and renal function and those with moderately impaired hepatic function presenting for hepatic transplantation.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),[ml] / [kg·min],5.1,1597,DB00732,Atracurium besylate
,3778789,clearance,"There were no significant differences in volume of distribution (area) (139 v. 152 ml kg-1), clearance (5.1 v. 5.3 ml kg-1 min-1), T1/2 alpha (2.1 v. 2.0 min), or T1/2 beta (19.1 v. 20.3 min) between children with normal hepatic and renal function and those with moderately impaired hepatic function presenting for hepatic transplantation.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),[ml] / [kg·min],5.3,1598,DB00732,Atracurium besylate
,3778789,T1/2 alpha,"There were no significant differences in volume of distribution (area) (139 v. 152 ml kg-1), clearance (5.1 v. 5.3 ml kg-1 min-1), T1/2 alpha (2.1 v. 2.0 min), or T1/2 beta (19.1 v. 20.3 min) between children with normal hepatic and renal function and those with moderately impaired hepatic function presenting for hepatic transplantation.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),min,2.1,1599,DB00732,Atracurium besylate
,3778789,T1/2 alpha,"There were no significant differences in volume of distribution (area) (139 v. 152 ml kg-1), clearance (5.1 v. 5.3 ml kg-1 min-1), T1/2 alpha (2.1 v. 2.0 min), or T1/2 beta (19.1 v. 20.3 min) between children with normal hepatic and renal function and those with moderately impaired hepatic function presenting for hepatic transplantation.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),min,2.0,1600,DB00732,Atracurium besylate
,3778789,T1/2 beta,"There were no significant differences in volume of distribution (area) (139 v. 152 ml kg-1), clearance (5.1 v. 5.3 ml kg-1 min-1), T1/2 alpha (2.1 v. 2.0 min), or T1/2 beta (19.1 v. 20.3 min) between children with normal hepatic and renal function and those with moderately impaired hepatic function presenting for hepatic transplantation.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),min,19.1,1601,DB00732,Atracurium besylate
,3778789,T1/2 beta,"There were no significant differences in volume of distribution (area) (139 v. 152 ml kg-1), clearance (5.1 v. 5.3 ml kg-1 min-1), T1/2 alpha (2.1 v. 2.0 min), or T1/2 beta (19.1 v. 20.3 min) between children with normal hepatic and renal function and those with moderately impaired hepatic function presenting for hepatic transplantation.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),min,20.3,1602,DB00732,Atracurium besylate
,3778789,volume of distribution (area),There were significant differences in volume of distribution (area) (176 v. 139 ml kg-1) and in clearance of atracurium (9.1 v.,Pharmacokinetics of atracurium in anaesthetized infants and children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),[ml] / [kg],176,1603,DB00732,Atracurium besylate
,3778789,volume of distribution (area),There were significant differences in volume of distribution (area) (176 v. 139 ml kg-1) and in clearance of atracurium (9.1 v.,Pharmacokinetics of atracurium in anaesthetized infants and children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),[ml] / [kg],139,1604,DB00732,Atracurium besylate
,3778789,clearance,There were significant differences in volume of distribution (area) (176 v. 139 ml kg-1) and in clearance of atracurium (9.1 v.,Pharmacokinetics of atracurium in anaesthetized infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),,9.1,1605,DB00732,Atracurium besylate
,3778789,clearance,"In infants the clearance of atracurium in ml m-2 min-1 (153 v. 133) tended to be greater and the T1/2 alpha and T1/2 beta tended to be shorter (1.0 v. 2.0 and 13.6 v. 19.1) than in children with normal excretory function; however, these trends did not reach statistical significance.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),[ml] / [(m)^2·min],153,1606,DB00732,Atracurium besylate
,3778789,clearance,"In infants the clearance of atracurium in ml m-2 min-1 (153 v. 133) tended to be greater and the T1/2 alpha and T1/2 beta tended to be shorter (1.0 v. 2.0 and 13.6 v. 19.1) than in children with normal excretory function; however, these trends did not reach statistical significance.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),[ml] / [(m)^2·min],133,1607,DB00732,Atracurium besylate
,3778789,T1/2 alpha,"In infants the clearance of atracurium in ml m-2 min-1 (153 v. 133) tended to be greater and the T1/2 alpha and T1/2 beta tended to be shorter (1.0 v. 2.0 and 13.6 v. 19.1) than in children with normal excretory function; however, these trends did not reach statistical significance.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),[ml] / [(m)^2·min],1.0,1608,DB00732,Atracurium besylate
,3778789,T1/2 beta,"In infants the clearance of atracurium in ml m-2 min-1 (153 v. 133) tended to be greater and the T1/2 alpha and T1/2 beta tended to be shorter (1.0 v. 2.0 and 13.6 v. 19.1) than in children with normal excretory function; however, these trends did not reach statistical significance.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),,2.0,1609,DB00732,Atracurium besylate
,3778789,T1/2 beta,"In infants the clearance of atracurium in ml m-2 min-1 (153 v. 133) tended to be greater and the T1/2 alpha and T1/2 beta tended to be shorter (1.0 v. 2.0 and 13.6 v. 19.1) than in children with normal excretory function; however, these trends did not reach statistical significance.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),,13.6,1610,DB00732,Atracurium besylate
,3778789,T1/2 beta,"In infants the clearance of atracurium in ml m-2 min-1 (153 v. 133) tended to be greater and the T1/2 alpha and T1/2 beta tended to be shorter (1.0 v. 2.0 and 13.6 v. 19.1) than in children with normal excretory function; however, these trends did not reach statistical significance.",Pharmacokinetics of atracurium in anaesthetized infants and children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778789/),,19.1,1611,DB00732,Atracurium besylate
,8624002,Onset of,"Onset of block was delayed in the elderly; values being mean 3.0 (95% confidence interval 1.75-11.4) min and 4.0 (2.4-6.5) min in the young and elderly, respectively (P < 0.01).",Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624002/),min,3.0,4027,DB00732,Atracurium besylate
,8624002,Onset of,"Onset of block was delayed in the elderly; values being mean 3.0 (95% confidence interval 1.75-11.4) min and 4.0 (2.4-6.5) min in the young and elderly, respectively (P < 0.01).",Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624002/),min,4.0,4028,DB00732,Atracurium besylate
,8624002,Plasma clearance,Plasma clearance was 319 (293-345) ml/min in the study population and did not differ between young and elderly patients.,Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624002/),[ml] / [min],319,4029,DB00732,Atracurium besylate
,8624002,Apparent volume of distribution,"Apparent volume of distribution was 13.28 (9.9-16.7) 1 and 9.6 (7.6-11.7) 1 in the elderly and young adults, respectively (P < 0.05).",Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624002/),1,13.28,4030,DB00732,Atracurium besylate
,8624002,Apparent volume of distribution,"Apparent volume of distribution was 13.28 (9.9-16.7) 1 and 9.6 (7.6-11.7) 1 in the elderly and young adults, respectively (P < 0.05).",Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624002/),1,9.6,4031,DB00732,Atracurium besylate
,8624002,rate of biophase equilibration (ke0),There also were differences in pharmacodynamic parameters between the young and elderly; the predominant change being a slower rate of biophase equilibration (ke0) in the elderly (0.060 [0.052-0.068])/min compared with the young (0.071 [0.065-0.077]/min; P < 0.05).,Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624002/),,0.060,4032,DB00732,Atracurium besylate
,8624002,rate of biophase equilibration (ke0),There also were differences in pharmacodynamic parameters between the young and elderly; the predominant change being a slower rate of biophase equilibration (ke0) in the elderly (0.060 [0.052-0.068])/min compared with the young (0.071 [0.065-0.077]/min; P < 0.05).,Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624002/),1/[min],0.071,4033,DB00732,Atracurium besylate
,2265046,operating time,The mean operating time was 92 min and the mean duration of infusion was 59 min.,A computer designed graph for administration of atracurium by i.v. infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265046/),min,92,10773,DB00732,Atracurium besylate
,2265046,duration of infusion,The mean operating time was 92 min and the mean duration of infusion was 59 min.,A computer designed graph for administration of atracurium by i.v. infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265046/),min,59,10774,DB00732,Atracurium besylate
,2394062,terminal half-life,"Renal failure was defined as a creatinine clearance of less than 5 ml/min; it caused no significant differences in the pharmacokinetics of atracurium but did result in a different pharmacokinetic profile of laudanosine, with a 3-fold increase in the mean ( +/- SD) terminal half-life (176 +/- 84 and 516 +/- 262 minutes for patients with normal and impaired renal function, respectively).",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,176,19818,DB00732,Atracurium besylate
,2394062,terminal half-life,"Renal failure was defined as a creatinine clearance of less than 5 ml/min; it caused no significant differences in the pharmacokinetics of atracurium but did result in a different pharmacokinetic profile of laudanosine, with a 3-fold increase in the mean ( +/- SD) terminal half-life (176 +/- 84 and 516 +/- 262 minutes for patients with normal and impaired renal function, respectively).",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,516,19819,DB00732,Atracurium besylate
,2394062,half-life,"Moreover, the half-life of the quaternary alcohol increased from 27.1 +/- 8.3 minutes in patients with normal renal function to 42.5 +/- 8.3 minutes in those with impaired renal function (mean +/- SD).",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,27.1,19820,DB00732,Atracurium besylate
,2394062,half-life,"Moreover, the half-life of the quaternary alcohol increased from 27.1 +/- 8.3 minutes in patients with normal renal function to 42.5 +/- 8.3 minutes in those with impaired renal function (mean +/- SD).",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,42.5,19821,DB00732,Atracurium besylate
,2394062,total duration of neuromuscular blockade,"The total duration of neuromuscular blockade (51.8 +/- 11.5 minutes) and the recovery index (9.6 +/- 2.0 minutes) are shortened in patients with impaired renal function, compared with those with normal renal function (64.1 +/- 7.2 and 16.7 +/- 4.1 minutes, respectively), indicating that sensitivity to the neuromuscular blocking action of atracurium may be altered by renal failure.",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,51.8,19822,DB00732,Atracurium besylate
,2394062,recovery index,"The total duration of neuromuscular blockade (51.8 +/- 11.5 minutes) and the recovery index (9.6 +/- 2.0 minutes) are shortened in patients with impaired renal function, compared with those with normal renal function (64.1 +/- 7.2 and 16.7 +/- 4.1 minutes, respectively), indicating that sensitivity to the neuromuscular blocking action of atracurium may be altered by renal failure.",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,9.6,19823,DB00732,Atracurium besylate
,2394062,recovery index,"The total duration of neuromuscular blockade (51.8 +/- 11.5 minutes) and the recovery index (9.6 +/- 2.0 minutes) are shortened in patients with impaired renal function, compared with those with normal renal function (64.1 +/- 7.2 and 16.7 +/- 4.1 minutes, respectively), indicating that sensitivity to the neuromuscular blocking action of atracurium may be altered by renal failure.",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,64.1,19824,DB00732,Atracurium besylate
,2394062,recovery index,"The total duration of neuromuscular blockade (51.8 +/- 11.5 minutes) and the recovery index (9.6 +/- 2.0 minutes) are shortened in patients with impaired renal function, compared with those with normal renal function (64.1 +/- 7.2 and 16.7 +/- 4.1 minutes, respectively), indicating that sensitivity to the neuromuscular blocking action of atracurium may be altered by renal failure.",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,16.7,19825,DB00732,Atracurium besylate
,2029828,rate constant,"Nonparametric analysis yielded (mean +/- SEM) a rate constant, concentration for 50% blockade, and slope of the effect-concentration relationship of 0.092 +/- 0.01 min-1, 379 +/- 27 ng/ml, and 7.3 +/- 1.67, respectively, when based on arterial samples.",Pharmacokinetics and pharmacodynamics of atracurium obtained with arterial and venous blood samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029828/),1/[min],0.092,38099,DB00732,Atracurium besylate
,2029828,slope of the effect-concentration relationship,"Nonparametric analysis yielded (mean +/- SEM) a rate constant, concentration for 50% blockade, and slope of the effect-concentration relationship of 0.092 +/- 0.01 min-1, 379 +/- 27 ng/ml, and 7.3 +/- 1.67, respectively, when based on arterial samples.",Pharmacokinetics and pharmacodynamics of atracurium obtained with arterial and venous blood samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029828/),,7.3,38100,DB00732,Atracurium besylate
,2369806,elimination half-life,"No difference was observed between obese patients and nonobese patients in atracurium elimination half-life (19.8 +/- 0.7 versus 19.7 +/- 0.7 minutes), volume of distribution at steady state (8.6 +/- 0.7 versus 8.5 +/- 0.7 L), and total clearance (444 +/- 29 versus 404 +/- 25 ml/min).",Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369806/),min,19.8,46929,DB00732,Atracurium besylate
,2369806,elimination half-life,"No difference was observed between obese patients and nonobese patients in atracurium elimination half-life (19.8 +/- 0.7 versus 19.7 +/- 0.7 minutes), volume of distribution at steady state (8.6 +/- 0.7 versus 8.5 +/- 0.7 L), and total clearance (444 +/- 29 versus 404 +/- 25 ml/min).",Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369806/),min,19.7,46930,DB00732,Atracurium besylate
,2369806,volume of distribution at steady state,"No difference was observed between obese patients and nonobese patients in atracurium elimination half-life (19.8 +/- 0.7 versus 19.7 +/- 0.7 minutes), volume of distribution at steady state (8.6 +/- 0.7 versus 8.5 +/- 0.7 L), and total clearance (444 +/- 29 versus 404 +/- 25 ml/min).",Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369806/),l,8.6,46931,DB00732,Atracurium besylate
,2369806,volume of distribution at steady state,"No difference was observed between obese patients and nonobese patients in atracurium elimination half-life (19.8 +/- 0.7 versus 19.7 +/- 0.7 minutes), volume of distribution at steady state (8.6 +/- 0.7 versus 8.5 +/- 0.7 L), and total clearance (444 +/- 29 versus 404 +/- 25 ml/min).",Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369806/),l,8.5,46932,DB00732,Atracurium besylate
,2369806,total clearance,"No difference was observed between obese patients and nonobese patients in atracurium elimination half-life (19.8 +/- 0.7 versus 19.7 +/- 0.7 minutes), volume of distribution at steady state (8.6 +/- 0.7 versus 8.5 +/- 0.7 L), and total clearance (444 +/- 29 versus 404 +/- 25 ml/min).",Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369806/),[ml] / [min],444,46933,DB00732,Atracurium besylate
,2369806,total clearance,"No difference was observed between obese patients and nonobese patients in atracurium elimination half-life (19.8 +/- 0.7 versus 19.7 +/- 0.7 minutes), volume of distribution at steady state (8.6 +/- 0.7 versus 8.5 +/- 0.7 L), and total clearance (444 +/- 29 versus 404 +/- 25 ml/min).",Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369806/),[ml] / [min],404,46934,DB00732,Atracurium besylate
,2369806,volume of distribution at steady state,"However, if values were expressed on a total body weight basis, there was a difference between obese and nonobese patients in the volume of distribution at steady state (0.067 versus 0.141 L/kg) and total clearance (3.5 +/- 0.2 versus 6.6 +/- 0.5 ml/min/kg).",Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369806/),[l] / [kg],0.067,46935,DB00732,Atracurium besylate
,2369806,volume of distribution at steady state,"However, if values were expressed on a total body weight basis, there was a difference between obese and nonobese patients in the volume of distribution at steady state (0.067 versus 0.141 L/kg) and total clearance (3.5 +/- 0.2 versus 6.6 +/- 0.5 ml/min/kg).",Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369806/),[l] / [kg],0.141,46936,DB00732,Atracurium besylate
,2369806,total clearance,"However, if values were expressed on a total body weight basis, there was a difference between obese and nonobese patients in the volume of distribution at steady state (0.067 versus 0.141 L/kg) and total clearance (3.5 +/- 0.2 versus 6.6 +/- 0.5 ml/min/kg).",Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369806/),[ml] / [kg·min],3.5,46937,DB00732,Atracurium besylate
,2369806,total clearance,"However, if values were expressed on a total body weight basis, there was a difference between obese and nonobese patients in the volume of distribution at steady state (0.067 versus 0.141 L/kg) and total clearance (3.5 +/- 0.2 versus 6.6 +/- 0.5 ml/min/kg).",Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369806/),[ml] / [kg·min],6.6,46938,DB00732,Atracurium besylate
,2369806,effective concentration,"Consequently, the median effective concentration was higher in obese than in nonobese patients (470 +/- 46 versus 312 +/- 33 ng/ml).",Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369806/),[ng] / [ml],470,46939,DB00732,Atracurium besylate
,2369806,effective concentration,"Consequently, the median effective concentration was higher in obese than in nonobese patients (470 +/- 46 versus 312 +/- 33 ng/ml).",Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369806/),[ng] / [ml],312,46940,DB00732,Atracurium besylate
,8659778,Onset to 90% paralysis,Onset to 90% paralysis (mean +/- SD) was delayed in the elderly (3.4 +/- 1.0 vs. 2.5 +/- 0.6 min).,Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),min,3.4,51558,DB00732,Atracurium besylate
,8659778,Onset to 90% paralysis,Onset to 90% paralysis (mean +/- SD) was delayed in the elderly (3.4 +/- 1.0 vs. 2.5 +/- 0.6 min).,Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),min,2.5,51559,DB00732,Atracurium besylate
,8659778,Elimination half-life,Elimination half-life was minimally prolonged in the elderly (25.5 +/- 3.7 vs. 21.5 +/- 2.4 min).,Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),min,25.5,51560,DB00732,Atracurium besylate
,8659778,Elimination half-life,Elimination half-life was minimally prolonged in the elderly (25.5 +/- 3.7 vs. 21.5 +/- 2.4 min).,Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),min,21.5,51561,DB00732,Atracurium besylate
,8659778,Vss,"The Vss was larger in the elderly (126 +/- 16 vs. 108 +/- 13 ml/kg), although the clearances were the same for the two groups (5.0 +/- 0.9 vs. 4.6 +/- 0.8 ml.kg(-1).min(-1).",Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),[ml] / [kg],126,51562,DB00732,Atracurium besylate
,8659778,Vss,"The Vss was larger in the elderly (126 +/- 16 vs. 108 +/- 13 ml/kg), although the clearances were the same for the two groups (5.0 +/- 0.9 vs. 4.6 +/- 0.8 ml.kg(-1).min(-1).",Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),[ml] / [kg],108,51563,DB00732,Atracurium besylate
,8659778,clearances,"The Vss was larger in the elderly (126 +/- 16 vs. 108 +/- 13 ml/kg), although the clearances were the same for the two groups (5.0 +/- 0.9 vs. 4.6 +/- 0.8 ml.kg(-1).min(-1).",Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),[ml] / [kg·min],5.0,51564,DB00732,Atracurium besylate
,8659778,clearances,"The Vss was larger in the elderly (126 +/- 16 vs. 108 +/- 13 ml/kg), although the clearances were the same for the two groups (5.0 +/- 0.9 vs. 4.6 +/- 0.8 ml.kg(-1).min(-1).",Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),[ml] / [kg·min],4.6,51565,DB00732,Atracurium besylate
,8659778,time to onset,"These differences are not associated with changes in recovery profile after a single bolus dose, although the mean time to onset was approximately 1 min longer in elderly patients.",Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),min,1,51566,DB00732,Atracurium besylate
> or =,8602660,train-of-four ratio,All patients were allowed to recover spontaneously to a train-of-four ratio > or = 0.70 after cisatracurium-induced neuromuscular block.,Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),,0.70,54591,DB00732,Atracurium besylate
,8602660,clearances,The clearances (5.28 +/- 1.23 vs.,Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),,5.28,54592,DB00732,Atracurium besylate
,8602660,terminal elimination half-lives,"4.66 +/- 0.67 ml x min(-1) x kg(-1) and terminal elimination half-lives (22.4 +/- 2.7 vs. 25.5 +/- 4.1 min) were not statistically different between patients receiving 0.1 mg x kg(-1) and 0.2 mg x kg(-1), respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),min,22.4,54593,DB00732,Atracurium besylate
,8602660,terminal elimination half-lives,"4.66 +/- 0.67 ml x min(-1) x kg(-1) and terminal elimination half-lives (22.4 +/- 2.7 vs. 25.5 +/- 4.1 min) were not statistically different between patients receiving 0.1 mg x kg(-1) and 0.2 mg x kg(-1), respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),min,25.5,54594,DB00732,Atracurium besylate
,8602660,Maximum concentration,"Maximum concentration values for laudanosine averaged 38 +/- 21 and 103 +/- 34 ng x ml(-1) for patients receiving the 0.1 and 0.2 mg x kg(-1) doses, respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),[ng] / [ml],38,54595,DB00732,Atracurium besylate
,8602660,Maximum concentration,"Maximum concentration values for laudanosine averaged 38 +/- 21 and 103 +/- 34 ng x ml(-1) for patients receiving the 0.1 and 0.2 mg x kg(-1) doses, respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),[ng] / [ml],103,54596,DB00732,Atracurium besylate
,8602660,Maximum concentration,"Maximum concentration values for monoquaternary alcohol averaged 101 +/- 27 and 253 +/- 51 ng x ml(-1), respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),[ng] / [ml],101,54597,DB00732,Atracurium besylate
,8602660,Maximum concentration,"Maximum concentration values for monoquaternary alcohol averaged 101 +/- 27 and 253 +/- 51 ng x ml(-1), respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),[ng] / [ml],253,54598,DB00732,Atracurium besylate
,2301759,elimination half-life,The increase in Vss without an age-related increase in Cltotal resulted in a longer elimination half-life [21.8 (+)/- 3.3 vs.,Pharmacokinetics and pharmacodynamics of atracurium in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2301759/),,21.8,57845,DB00732,Atracurium besylate
,7113256,plasma elimination half life,3. The plasma elimination half life of atracurium after administration via the jugular vein was c. 20 min.,Metabolic studies in the cat with atracurium: a neuromuscular blocking agent designed for non-enzymic inactivation at physiological pH. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7113256/),min,c,60294,DB00732,Atracurium besylate
,7113256,plasma elimination half life,3. The plasma elimination half life of atracurium after administration via the jugular vein was c. 20 min.,Metabolic studies in the cat with atracurium: a neuromuscular blocking agent designed for non-enzymic inactivation at physiological pH. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7113256/),min,20,60295,DB00732,Atracurium besylate
,22114771,Steady-state volume of distribution,Steady-state volume of distribution was determined to be 111 ± 71 ml kg(-1) and plasma clearance was 5.2 ± 1.8 ml min(-1) kg(-1) in these patients with greater inter-patient variability compared with other populations.,The pharmacokinetics and pharmacodynamics of cisatracurium in critically ill patients with severe sepsis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22114771/),[ml] / [kg],111,61087,DB00732,Atracurium besylate
,22114771,plasma clearance,Steady-state volume of distribution was determined to be 111 ± 71 ml kg(-1) and plasma clearance was 5.2 ± 1.8 ml min(-1) kg(-1) in these patients with greater inter-patient variability compared with other populations.,The pharmacokinetics and pharmacodynamics of cisatracurium in critically ill patients with severe sepsis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22114771/),[ml] / [kg·min],5.2,61088,DB00732,Atracurium besylate
,22114771,time to maximum block,"The time to maximum block (8.3 ± 2.9 min) and delay time of transferring from central to effect compartment (17.2 min) was much longer, while the maximum block (95.0 ± 6.3%) was less compared with those in other patient populations.",The pharmacokinetics and pharmacodynamics of cisatracurium in critically ill patients with severe sepsis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22114771/),min,8.3,61089,DB00732,Atracurium besylate
,22114771,time of transferring from central to effect compartment,"The time to maximum block (8.3 ± 2.9 min) and delay time of transferring from central to effect compartment (17.2 min) was much longer, while the maximum block (95.0 ± 6.3%) was less compared with those in other patient populations.",The pharmacokinetics and pharmacodynamics of cisatracurium in critically ill patients with severe sepsis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22114771/),min,17.2,61090,DB00732,Atracurium besylate
,22114771,effect compartment concentration resulting in,The effect compartment concentration resulting in 50% of maximum effect (128 ± 58 ng ml(-1)) was larger than previously described.,The pharmacokinetics and pharmacodynamics of cisatracurium in critically ill patients with severe sepsis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22114771/),[ng] / [ml],128,61091,DB00732,Atracurium besylate
,9349062,times to 90%,"The times to 90% and maximum depression of the first twitch of the train-of-four were significantly longer after cisatracurium than atracurium (2.2 and 3.4 min compared with 1.3 and 1.8 min, respectively; p < 0.01 in each instance).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,2.2,80742,DB00732,Atracurium besylate
,9349062,times to 90%,"The times to 90% and maximum depression of the first twitch of the train-of-four were significantly longer after cisatracurium than atracurium (2.2 and 3.4 min compared with 1.3 and 1.8 min, respectively; p < 0.01 in each instance).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,3.4,80743,DB00732,Atracurium besylate
,9349062,times to 90%,"The times to 90% and maximum depression of the first twitch of the train-of-four were significantly longer after cisatracurium than atracurium (2.2 and 3.4 min compared with 1.3 and 1.8 min, respectively; p < 0.01 in each instance).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,1.3,80744,DB00732,Atracurium besylate
,9349062,maximum depression of the first twitch,"The times to 90% and maximum depression of the first twitch of the train-of-four were significantly longer after cisatracurium than atracurium (2.2 and 3.4 min compared with 1.3 and 1.8 min, respectively; p < 0.01 in each instance).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,3.4,80745,DB00732,Atracurium besylate
,9349062,maximum depression of the first twitch,"The times to 90% and maximum depression of the first twitch of the train-of-four were significantly longer after cisatracurium than atracurium (2.2 and 3.4 min compared with 1.3 and 1.8 min, respectively; p < 0.01 in each instance).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,1.8,80746,DB00732,Atracurium besylate
,9349062,clearance,"The different isomer groups of atracurium have different pharmacokinetics, the trans-trans group having the highest clearance (1440 ml.min-1) and the cis-cis group the lowest (499 ml.min-1).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),[ml] / [min],1440,80747,DB00732,Atracurium besylate
,9349062,clearance,"The different isomer groups of atracurium have different pharmacokinetics, the trans-trans group having the highest clearance (1440 ml.min-1) and the cis-cis group the lowest (499 ml.min-1).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),[ml] / [min],499,80748,DB00732,Atracurium besylate
,9349062,clearance,"The clearance of cisatracurium (425 ml.min-1) is less than that of cis-cis atracurium and its elimination half-life is longer (34.9 min and 21.9 min, respectively).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),[ml] / [min],425,80749,DB00732,Atracurium besylate
,9349062,elimination half-life,"The clearance of cisatracurium (425 ml.min-1) is less than that of cis-cis atracurium and its elimination half-life is longer (34.9 min and 21.9 min, respectively).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,34.9,80750,DB00732,Atracurium besylate
,9349062,elimination half-life,"The clearance of cisatracurium (425 ml.min-1) is less than that of cis-cis atracurium and its elimination half-life is longer (34.9 min and 21.9 min, respectively).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,21.9,80751,DB00732,Atracurium besylate
,8785138,infusion time,"The mean infusion time in group 1 was 37.6 h and in group 2, 27.5 h.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),h,37.6,90953,DB00732,Atracurium besylate
,8785138,infusion time,"The mean infusion time in group 1 was 37.6 h and in group 2, 27.5 h.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),h,27.5,90954,DB00732,Atracurium besylate
,8785138,time for the TOF ratio,"On termination of the infusion, the time for the TOF ratio to reach 0.7 was similar in the two groups (group 1 = 60 min; group 2 = 62 min).",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),min,0.7,90955,DB00732,Atracurium besylate
,8785138,time for the TOF ratio,"On termination of the infusion, the time for the TOF ratio to reach 0.7 was similar in the two groups (group 1 = 60 min; group 2 = 62 min).",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),min,60,90956,DB00732,Atracurium besylate
,8785138,time for the TOF ratio,"On termination of the infusion, the time for the TOF ratio to reach 0.7 was similar in the two groups (group 1 = 60 min; group 2 = 62 min).",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),min,62,90957,DB00732,Atracurium besylate
,8785138,infusion rate,The mean infusion rate of cis-atracurium was 0.19 mg kg-1 h-1 and of atracurium 0.47 mg kg-1 h-1 (expressed as mg of bis-cation): cis-atracurium was 2.5 times more potent than atracurium.,Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),[mg] / [h·kg],0.19,90958,DB00732,Atracurium besylate
,8785138,infusion rate,The mean infusion rate of cis-atracurium was 0.19 mg kg-1 h-1 and of atracurium 0.47 mg kg-1 h-1 (expressed as mg of bis-cation): cis-atracurium was 2.5 times more potent than atracurium.,Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),[mg] / [h·kg],0.47,90959,DB00732,Atracurium besylate
,8785138,volume of distribution (V),"The mean population pharmacokinetic values for cis-atracurium were: volume of distribution (V) = 21,900 (SEM 416) ml; clearance (Cl) = 549 (79) ml min-1; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of atracurium isomers were: cis-cis, V = 15,100 (720) ml, Cl = 449 (42) ml min-1, T1/2 = 23.4 (1.2) min; cis-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml min-1, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml min-1, T1/2 = 5.8 (0.4) min.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),ml,"21,900",90960,DB00732,Atracurium besylate
,8785138,clearance (Cl),"The mean population pharmacokinetic values for cis-atracurium were: volume of distribution (V) = 21,900 (SEM 416) ml; clearance (Cl) = 549 (79) ml min-1; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of atracurium isomers were: cis-cis, V = 15,100 (720) ml, Cl = 449 (42) ml min-1, T1/2 = 23.4 (1.2) min; cis-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml min-1, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml min-1, T1/2 = 5.8 (0.4) min.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),[ml] / [min],549,90961,DB00732,Atracurium besylate
,8785138,half-life (T1/2),"The mean population pharmacokinetic values for cis-atracurium were: volume of distribution (V) = 21,900 (SEM 416) ml; clearance (Cl) = 549 (79) ml min-1; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of atracurium isomers were: cis-cis, V = 15,100 (720) ml, Cl = 449 (42) ml min-1, T1/2 = 23.4 (1.2) min; cis-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml min-1, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml min-1, T1/2 = 5.8 (0.4) min.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),min,27.6,90962,DB00732,Atracurium besylate
,8785138,V,"The mean population pharmacokinetic values for cis-atracurium were: volume of distribution (V) = 21,900 (SEM 416) ml; clearance (Cl) = 549 (79) ml min-1; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of atracurium isomers were: cis-cis, V = 15,100 (720) ml, Cl = 449 (42) ml min-1, T1/2 = 23.4 (1.2) min; cis-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml min-1, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml min-1, T1/2 = 5.8 (0.4) min.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),ml,"15,100",90963,DB00732,Atracurium besylate
,8785138,Cl,"The mean population pharmacokinetic values for cis-atracurium were: volume of distribution (V) = 21,900 (SEM 416) ml; clearance (Cl) = 549 (79) ml min-1; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of atracurium isomers were: cis-cis, V = 15,100 (720) ml, Cl = 449 (42) ml min-1, T1/2 = 23.4 (1.2) min; cis-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml min-1, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml min-1, T1/2 = 5.8 (0.4) min.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),[ml] / [min],449,90964,DB00732,Atracurium besylate
,8785138,T1/2,"The mean population pharmacokinetic values for cis-atracurium were: volume of distribution (V) = 21,900 (SEM 416) ml; clearance (Cl) = 549 (79) ml min-1; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of atracurium isomers were: cis-cis, V = 15,100 (720) ml, Cl = 449 (42) ml min-1, T1/2 = 23.4 (1.2) min; cis-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml min-1, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml min-1, T1/2 = 5.8 (0.4) min.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),min,23.4,90965,DB00732,Atracurium besylate
,8785138,V,"The mean population pharmacokinetic values for cis-atracurium were: volume of distribution (V) = 21,900 (SEM 416) ml; clearance (Cl) = 549 (79) ml min-1; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of atracurium isomers were: cis-cis, V = 15,100 (720) ml, Cl = 449 (42) ml min-1, T1/2 = 23.4 (1.2) min; cis-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml min-1, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml min-1, T1/2 = 5.8 (0.4) min.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),ml,"18,000",90966,DB00732,Atracurium besylate
,8785138,Cl,"The mean population pharmacokinetic values for cis-atracurium were: volume of distribution (V) = 21,900 (SEM 416) ml; clearance (Cl) = 549 (79) ml min-1; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of atracurium isomers were: cis-cis, V = 15,100 (720) ml, Cl = 449 (42) ml min-1, T1/2 = 23.4 (1.2) min; cis-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml min-1, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml min-1, T1/2 = 5.8 (0.4) min.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),[ml] / [min],1070,90967,DB00732,Atracurium besylate
,8785138,T1/2,"The mean population pharmacokinetic values for cis-atracurium were: volume of distribution (V) = 21,900 (SEM 416) ml; clearance (Cl) = 549 (79) ml min-1; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of atracurium isomers were: cis-cis, V = 15,100 (720) ml, Cl = 449 (42) ml min-1, T1/2 = 23.4 (1.2) min; cis-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml min-1, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml min-1, T1/2 = 5.8 (0.4) min.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),,11.7,90968,DB00732,Atracurium besylate
,8785138,V,"The mean population pharmacokinetic values for cis-atracurium were: volume of distribution (V) = 21,900 (SEM 416) ml; clearance (Cl) = 549 (79) ml min-1; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of atracurium isomers were: cis-cis, V = 15,100 (720) ml, Cl = 449 (42) ml min-1, T1/2 = 23.4 (1.2) min; cis-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml min-1, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml min-1, T1/2 = 5.8 (0.4) min.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),ml,"13,100",90969,DB00732,Atracurium besylate
,8785138,Cl,"The mean population pharmacokinetic values for cis-atracurium were: volume of distribution (V) = 21,900 (SEM 416) ml; clearance (Cl) = 549 (79) ml min-1; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of atracurium isomers were: cis-cis, V = 15,100 (720) ml, Cl = 449 (42) ml min-1, T1/2 = 23.4 (1.2) min; cis-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml min-1, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml min-1, T1/2 = 5.8 (0.4) min.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),[ml] / [min],1560,90970,DB00732,Atracurium besylate
,8785138,T1/2,"The mean population pharmacokinetic values for cis-atracurium were: volume of distribution (V) = 21,900 (SEM 416) ml; clearance (Cl) = 549 (79) ml min-1; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of atracurium isomers were: cis-cis, V = 15,100 (720) ml, Cl = 449 (42) ml min-1, T1/2 = 23.4 (1.2) min; cis-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml min-1, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml min-1, T1/2 = 5.8 (0.4) min.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),min,5.8,90971,DB00732,Atracurium besylate
,8785138,peak value,Plasma laudanosine concentrations were lower in the cis-atracurium (peak value 1.3 micrograms ml-1) than in the atracurium (maximum 4.4 micrograms ml-1) group.,Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),[μg] / [ml],1.3,90972,DB00732,Atracurium besylate
,8785138,peak value,Plasma laudanosine concentrations were lower in the cis-atracurium (peak value 1.3 micrograms ml-1) than in the atracurium (maximum 4.4 micrograms ml-1) group.,Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),[μg] / [ml],4.4,90973,DB00732,Atracurium besylate
,8785138,maximum,Plasma laudanosine concentrations were lower in the cis-atracurium (peak value 1.3 micrograms ml-1) than in the atracurium (maximum 4.4 micrograms ml-1) group.,Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),[μg] / [ml],4.4,90974,DB00732,Atracurium besylate
,6687550,distribution half-life (T1/2 alpha),"The results from the two groups were not significantly different, giving overall mean values of 2 min (+/- 0.2 SEM) for the distribution half-life (T1/2 alpha), 19.9 min (+/- 0.6) for the elimination half-life (T1/2 beta), 5.5 ml min-1 kg-1 (+/- 0.2) for total clearance (Cl) and 157 ml kg-1 (+/- 7) for total distribution volume (Varea).",Pharmacokinetics of atracurium besylate in healthy patients (after a single i.v. bolus dose). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6687550/),min,2,93092,DB00732,Atracurium besylate
,6687550,elimination half-life (T1/2 beta),"The results from the two groups were not significantly different, giving overall mean values of 2 min (+/- 0.2 SEM) for the distribution half-life (T1/2 alpha), 19.9 min (+/- 0.6) for the elimination half-life (T1/2 beta), 5.5 ml min-1 kg-1 (+/- 0.2) for total clearance (Cl) and 157 ml kg-1 (+/- 7) for total distribution volume (Varea).",Pharmacokinetics of atracurium besylate in healthy patients (after a single i.v. bolus dose). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6687550/),min,19.9,93093,DB00732,Atracurium besylate
,6687550,total clearance (Cl),"The results from the two groups were not significantly different, giving overall mean values of 2 min (+/- 0.2 SEM) for the distribution half-life (T1/2 alpha), 19.9 min (+/- 0.6) for the elimination half-life (T1/2 beta), 5.5 ml min-1 kg-1 (+/- 0.2) for total clearance (Cl) and 157 ml kg-1 (+/- 7) for total distribution volume (Varea).",Pharmacokinetics of atracurium besylate in healthy patients (after a single i.v. bolus dose). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6687550/),[ml] / [kg·min],5.5,93094,DB00732,Atracurium besylate
,6687550,total distribution volume (Varea),"The results from the two groups were not significantly different, giving overall mean values of 2 min (+/- 0.2 SEM) for the distribution half-life (T1/2 alpha), 19.9 min (+/- 0.6) for the elimination half-life (T1/2 beta), 5.5 ml min-1 kg-1 (+/- 0.2) for total clearance (Cl) and 157 ml kg-1 (+/- 7) for total distribution volume (Varea).",Pharmacokinetics of atracurium besylate in healthy patients (after a single i.v. bolus dose). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6687550/),[ml] / [kg],157,93095,DB00732,Atracurium besylate
,6689126,plasma elimination half-life,"The results from the two groups were not significantly different, giving a mean plasma elimination half-life of 22 min in patients with severe hepatic and renal failure and a mean of 21 min in the normal group.",Pharmacokinetics of atracurium in acute hepatic failure (with acute renal failure). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6689126/),min,22,97354,DB00732,Atracurium besylate
,6689126,plasma elimination half-life,"The results from the two groups were not significantly different, giving a mean plasma elimination half-life of 22 min in patients with severe hepatic and renal failure and a mean of 21 min in the normal group.",Pharmacokinetics of atracurium in acute hepatic failure (with acute renal failure). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6689126/),min,21,97355,DB00732,Atracurium besylate
,9646009,concentration ratio (UV/MV),The umbilical/maternal vein concentration ratio (UV/MV) of nondepolarising neuromuscular relaxants varies from 7 to 26% and clinical doses of these drugs may induce partial residual curarisation in neonates.,Clinical pharmacokinetics of neuromuscular relaxants in pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646009/),%,7 to 26,106950,DB00732,Atracurium besylate
,2633924,elimination half life,"Using a two-compartment pharmacokinetic model, the elimination half life was found to be 28.6 +/- 6.3 min (mean +/- SEM), the total volume of distribution 341 +/- 56 ml/kg and the plasma clearance 8.7 +/- 1.1 ml/min/kg.",Pharmacokinetics of atracurium besylate in the pig after a single i.v. injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633924/),min,28.6,107444,DB00732,Atracurium besylate
,2633924,total volume of distribution,"Using a two-compartment pharmacokinetic model, the elimination half life was found to be 28.6 +/- 6.3 min (mean +/- SEM), the total volume of distribution 341 +/- 56 ml/kg and the plasma clearance 8.7 +/- 1.1 ml/min/kg.",Pharmacokinetics of atracurium besylate in the pig after a single i.v. injection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633924/),[ml] / [kg],341,107445,DB00732,Atracurium besylate
,2633924,plasma clearance,"Using a two-compartment pharmacokinetic model, the elimination half life was found to be 28.6 +/- 6.3 min (mean +/- SEM), the total volume of distribution 341 +/- 56 ml/kg and the plasma clearance 8.7 +/- 1.1 ml/min/kg.",Pharmacokinetics of atracurium besylate in the pig after a single i.v. injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633924/),[ml] / [kg·min],8.7,107446,DB00732,Atracurium besylate
,15505447,recovery time,The median recovery time for train-of-four for cisatracurium (30 min) was less than that for vecuronium (180 min) (P < 0.05).,Comparison of cisatracurium and vecuronium by infusion in neonates and small infants after congenital heart surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15505447/),min,30,108572,DB00732,Atracurium besylate
,15505447,recovery time,The median recovery time for train-of-four for cisatracurium (30 min) was less than that for vecuronium (180 min) (P < 0.05).,Comparison of cisatracurium and vecuronium by infusion in neonates and small infants after congenital heart surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15505447/),min,180,108573,DB00732,Atracurium besylate
,2031815,volume of distribution,Mean (SEM) volume of distribution was slightly greater with previous suxamethonium (143 (13) ml kg-1) than without (109 (5) ml kg-1) (P less than 0.04).,Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031815/),[ml] / [kg],143,109862,DB00732,Atracurium besylate
,2031815,volume of distribution,Mean (SEM) volume of distribution was slightly greater with previous suxamethonium (143 (13) ml kg-1) than without (109 (5) ml kg-1) (P less than 0.04).,Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031815/),[ml] / [kg],109,109863,DB00732,Atracurium besylate
,2031815,elimination half-life,"Mean elimination half-life was unaffected (20.3 (0.8) min and 20.4 (1.6) min, respectively).",Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031815/),min,20.3,109864,DB00732,Atracurium besylate
,2031815,elimination half-life,"Mean elimination half-life was unaffected (20.3 (0.8) min and 20.4 (1.6) min, respectively).",Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031815/),min,20.4,109865,DB00732,Atracurium besylate
,2031815,concentration at 50% block (Cpss50),Atracurium concentration at 50% block (Cpss50) was 305 (30) ng ml-1 with and 454 (25) ng ml-1 without previous suxamethonium (P less than 0.01).,Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031815/),[ng] / [ml],305,109866,DB00732,Atracurium besylate
,2031815,concentration at 50% block (Cpss50),Atracurium concentration at 50% block (Cpss50) was 305 (30) ng ml-1 with and 454 (25) ng ml-1 without previous suxamethonium (P less than 0.01).,Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031815/),[ng] / [ml],454,109867,DB00732,Atracurium besylate
,11144993,elimination half-life,The elimination half-life of atracurium averaged 22 minutes.,Pharmacokinetic-pharmacodynamic modeling of atracurium in intensive care patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144993/),min,22,111283,DB00732,Atracurium besylate
,11144993,volume of distribution,"Mean volume of distribution and plasma clearance were 217 ml/kg and 550 ml/min, respectively.",Pharmacokinetic-pharmacodynamic modeling of atracurium in intensive care patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144993/),[ml] / [kg],217,111284,DB00732,Atracurium besylate
,11144993,plasma clearance,"Mean volume of distribution and plasma clearance were 217 ml/kg and 550 ml/min, respectively.",Pharmacokinetic-pharmacodynamic modeling of atracurium in intensive care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144993/),[ml] / [min],550,111285,DB00732,Atracurium besylate
,11144993,Emax,"The concentration producing 50% of the Emax was 1.36 micrograms/mL, and the mean ke0 was 0.059 min-1.",Pharmacokinetic-pharmacodynamic modeling of atracurium in intensive care patients. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144993/),[μg] / [ml],1.36,111286,DB00732,Atracurium besylate
,11144993,ke0,"The concentration producing 50% of the Emax was 1.36 micrograms/mL, and the mean ke0 was 0.059 min-1.",Pharmacokinetic-pharmacodynamic modeling of atracurium in intensive care patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144993/),1/[min],0.059,111287,DB00732,Atracurium besylate
,11144993,Recovery time,"Recovery time ranged from 30 to 80 minutes, and none of the patients of this study had residual paralysis.",Pharmacokinetic-pharmacodynamic modeling of atracurium in intensive care patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144993/),min,30 to 80,111288,DB00732,Atracurium besylate
,15673889,clearance,"The clearance of cisatracurium was significantly faster in Group A when compared with Group C (7.12 +/- 1.87 versus 5.72 +/- 0.70 L . kg(-1) . min(-1), P = 0.01).",Cisatracurium-induced neuromuscular blockade is affected by chronic phenytoin or carbamazepine treatment in neurosurgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15673889/),[l] / [kg·min],7.12,113790,DB00732,Atracurium besylate
,15673889,clearance,"The clearance of cisatracurium was significantly faster in Group A when compared with Group C (7.12 +/- 1.87 versus 5.72 +/- 0.70 L . kg(-1) . min(-1), P = 0.01).",Cisatracurium-induced neuromuscular blockade is affected by chronic phenytoin or carbamazepine treatment in neurosurgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15673889/),[l] / [kg·min],5.72,113791,DB00732,Atracurium besylate
,15673889,Cp(ss)95,"The Cp(ss)95 was also significantly larger in Group A (191 +/- 45 versus 159 +/- 36 ng/mL, P = 0.04).",Cisatracurium-induced neuromuscular blockade is affected by chronic phenytoin or carbamazepine treatment in neurosurgical patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15673889/),[ng] / [ml],191,113792,DB00732,Atracurium besylate
,15673889,Cp(ss)95,"The Cp(ss)95 was also significantly larger in Group A (191 +/- 45 versus 159 +/- 36 ng/mL, P = 0.04).",Cisatracurium-induced neuromuscular blockade is affected by chronic phenytoin or carbamazepine treatment in neurosurgical patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15673889/),[ng] / [ml],159,113793,DB00732,Atracurium besylate
,3207525,elimination half-life,Patients with renal failure had a significantly longer mean elimination half-life for laudanosine (1418 min v. 375 min; P less than 0.05) and Vd (4.52 litre kg-1 v. 2.40 litre kg-1; P less than 0.01) than the patients with normal renal function.,"Disposition of infusions of atracurium and its metabolite, laudanosine, in patients in renal and respiratory failure in an ITU. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207525/),min,1418,115497,DB00732,Atracurium besylate
,3207525,elimination half-life,Patients with renal failure had a significantly longer mean elimination half-life for laudanosine (1418 min v. 375 min; P less than 0.05) and Vd (4.52 litre kg-1 v. 2.40 litre kg-1; P less than 0.01) than the patients with normal renal function.,"Disposition of infusions of atracurium and its metabolite, laudanosine, in patients in renal and respiratory failure in an ITU. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207525/),min,375,115498,DB00732,Atracurium besylate
,3207525,Vd,Patients with renal failure had a significantly longer mean elimination half-life for laudanosine (1418 min v. 375 min; P less than 0.05) and Vd (4.52 litre kg-1 v. 2.40 litre kg-1; P less than 0.01) than the patients with normal renal function.,"Disposition of infusions of atracurium and its metabolite, laudanosine, in patients in renal and respiratory failure in an ITU. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207525/),[l] / [kg],4.52,115499,DB00732,Atracurium besylate
,3207525,Vd,Patients with renal failure had a significantly longer mean elimination half-life for laudanosine (1418 min v. 375 min; P less than 0.05) and Vd (4.52 litre kg-1 v. 2.40 litre kg-1; P less than 0.01) than the patients with normal renal function.,"Disposition of infusions of atracurium and its metabolite, laudanosine, in patients in renal and respiratory failure in an ITU. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207525/),[l] / [kg],2.40,115500,DB00732,Atracurium besylate
,11473869,plasma concentration,"The plasma concentration of cisatracurium during the infusion averaged 1.00 (0.25-1.45) microg/mL, expressed as median (range).",The pharmacokinetics of cisatracurium in patients with acute respiratory distress syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11473869/),[μg] / [ml],1.00,123156,DB00732,Atracurium besylate
,11473869,clearance,The clearance and half-life were 6.5 (3.3-7.6) mL. min(-1).,The pharmacokinetics of cisatracurium in patients with acute respiratory distress syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11473869/),[ml] / [min],6.5,123157,DB00732,Atracurium besylate
,11473869,plasma concentrations,The laudanosine plasma concentrations were 0.70 (0.12-1.20) microg/mL.,The pharmacokinetics of cisatracurium in patients with acute respiratory distress syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11473869/),[μg] / [ml],0.70,123158,DB00732,Atracurium besylate
,20444012,terminal elimination rate,Mean in vivo terminal elimination rate of cisatracurium (16.4 +/- 2.7 min) was twofold faster than mean in vitro degradation rate (32.9 +/- 3.7 min) in our dogs.,Studies on the pharmacokinetics of cisatracurium in anesthetized dogs: in vitro-in vivo correlations. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444012/),min,16.4,129247,DB00732,Atracurium besylate
,20444012,degradation rate,Mean in vivo terminal elimination rate of cisatracurium (16.4 +/- 2.7 min) was twofold faster than mean in vitro degradation rate (32.9 +/- 3.7 min) in our dogs.,Studies on the pharmacokinetics of cisatracurium in anesthetized dogs: in vitro-in vivo correlations. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444012/),min,32.9,129248,DB00732,Atracurium besylate
,20444012,Organ clearance,Organ clearance was 6.12 +/- 1.69 mL/min.kg and accounted for 56 +/- 12% of the total body clearance.,Studies on the pharmacokinetics of cisatracurium in anesthetized dogs: in vitro-in vivo correlations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444012/),[ml] / [kg·min],6.12,129249,DB00732,Atracurium besylate
,20444012,Apparent volume of distribution,"Apparent volume of distribution, an exit site-dependent parameter, averaged 212 or 184 mL/kg whether or not peripheral elimination was accounted for in the model.",Studies on the pharmacokinetics of cisatracurium in anesthetized dogs: in vitro-in vivo correlations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444012/),[ml] / [kg],212,129250,DB00732,Atracurium besylate
,20444012,Apparent volume of distribution,"Apparent volume of distribution, an exit site-dependent parameter, averaged 212 or 184 mL/kg whether or not peripheral elimination was accounted for in the model.",Studies on the pharmacokinetics of cisatracurium in anesthetized dogs: in vitro-in vivo correlations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444012/),[ml] / [kg],184,129251,DB00732,Atracurium besylate
,2719307,time to recover to 50% of maximal twitch depression,"The time course of effect was also similar, although the maximum twitch depression was significantly smaller (66.1% vs. 100% maximal twitch depression) and time to recover to 50% of maximal twitch depression was significantly shorter (14.2 vs. 52 min) in thermally injured patients.",Effect of thermal injury on the pharmacokinetics and pharmacodynamics of atracurium in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719307/),min,14.2,131508,DB00732,Atracurium besylate
,2719307,time to recover to 50% of maximal twitch depression,"The time course of effect was also similar, although the maximum twitch depression was significantly smaller (66.1% vs. 100% maximal twitch depression) and time to recover to 50% of maximal twitch depression was significantly shorter (14.2 vs. 52 min) in thermally injured patients.",Effect of thermal injury on the pharmacokinetics and pharmacodynamics of atracurium in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719307/),min,52,131509,DB00732,Atracurium besylate
,7488483,T1/2 beta,"The typical value of T1/2 beta was 4.2 min longer in renal failure than in the healthy patients (34.2 vs 30.0 min, P < 0.005).",Pharmacokinetics of 1R-cis 1'R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7488483/),min,34.2,131865,DB00732,Atracurium besylate
,7488483,T1/2 beta,"The typical value of T1/2 beta was 4.2 min longer in renal failure than in the healthy patients (34.2 vs 30.0 min, P < 0.005).",Pharmacokinetics of 1R-cis 1'R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7488483/),min,30.0,131866,DB00732,Atracurium besylate
,7488483,clearance,"In the healthy patients, clearance of 51W89 was greater in males, but it decreased with increasing age by approximately 1.5 ml min-1 yr-1.",Pharmacokinetics of 1R-cis 1'R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7488483/),[ml] / [min·yr],1.5,131867,DB00732,Atracurium besylate
,27582302,time to the maximal neuromuscular blocking effect,The time to the maximal neuromuscular blocking effect of cisatracurium was delayed in the MR group (2.08 min in the control group vs. 4.12 min in the MR group).,Altered pharmacodynamics and pharmacokinetics of cisatracurium in patients with severe mitral valve regurgitation during anaesthetic induction period. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27582302/),min,2.08,133757,DB00732,Atracurium besylate
,27582302,time to the maximal neuromuscular blocking effect,The time to the maximal neuromuscular blocking effect of cisatracurium was delayed in the MR group (2.08 min in the control group vs. 4.12 min in the MR group).,Altered pharmacodynamics and pharmacokinetics of cisatracurium in patients with severe mitral valve regurgitation during anaesthetic induction period. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27582302/),min,4.12,133758,DB00732,Atracurium besylate
,2360737,Volume of distribution at steady state,"Volume of distribution at steady state (210 +/- 118, 129 +/- 44, and 100 +/- 22 ml/kg for infants, children, and adults, respectively) and total clearance (7.9 +/- 2.0, 6.8 +/- 1.6, and 5.3 +/- 0.9 ml.kg-1.min-1 for the three groups) decreased with increasing age.",Pharmacokinetics and pharmacodynamics of atracurium in infants and children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360737/),[ml] / [kg],210,140669,DB00732,Atracurium besylate
,2360737,Volume of distribution at steady state,"Volume of distribution at steady state (210 +/- 118, 129 +/- 44, and 100 +/- 22 ml/kg for infants, children, and adults, respectively) and total clearance (7.9 +/- 2.0, 6.8 +/- 1.6, and 5.3 +/- 0.9 ml.kg-1.min-1 for the three groups) decreased with increasing age.",Pharmacokinetics and pharmacodynamics of atracurium in infants and children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360737/),[ml] / [kg],129,140670,DB00732,Atracurium besylate
,2360737,Volume of distribution at steady state,"Volume of distribution at steady state (210 +/- 118, 129 +/- 44, and 100 +/- 22 ml/kg for infants, children, and adults, respectively) and total clearance (7.9 +/- 2.0, 6.8 +/- 1.6, and 5.3 +/- 0.9 ml.kg-1.min-1 for the three groups) decreased with increasing age.",Pharmacokinetics and pharmacodynamics of atracurium in infants and children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360737/),[ml] / [kg],100,140671,DB00732,Atracurium besylate
,2360737,total clearance,"Volume of distribution at steady state (210 +/- 118, 129 +/- 44, and 100 +/- 22 ml/kg for infants, children, and adults, respectively) and total clearance (7.9 +/- 2.0, 6.8 +/- 1.6, and 5.3 +/- 0.9 ml.kg-1.min-1 for the three groups) decreased with increasing age.",Pharmacokinetics and pharmacodynamics of atracurium in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360737/),[ml] / [kg·min],7.9,140672,DB00732,Atracurium besylate
,2360737,total clearance,"Volume of distribution at steady state (210 +/- 118, 129 +/- 44, and 100 +/- 22 ml/kg for infants, children, and adults, respectively) and total clearance (7.9 +/- 2.0, 6.8 +/- 1.6, and 5.3 +/- 0.9 ml.kg-1.min-1 for the three groups) decreased with increasing age.",Pharmacokinetics and pharmacodynamics of atracurium in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360737/),[ml] / [kg·min],6.8,140673,DB00732,Atracurium besylate
,2360737,total clearance,"Volume of distribution at steady state (210 +/- 118, 129 +/- 44, and 100 +/- 22 ml/kg for infants, children, and adults, respectively) and total clearance (7.9 +/- 2.0, 6.8 +/- 1.6, and 5.3 +/- 0.9 ml.kg-1.min-1 for the three groups) decreased with increasing age.",Pharmacokinetics and pharmacodynamics of atracurium in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360737/),[ml] / [kg·min],5.3,140674,DB00732,Atracurium besylate
,2360737,elimination half-life,"Neither elimination half-life (20.0 +/- 5.1, 17.2 +/- 5.1, and 15.7 +/- 2.5 min for the three groups) nor the steady state plasma concentration that resulted in 50% neuromuscular blockade (363 +/- 118, 444 +/- 121, and 436 +/- 122 ng/ml for the three groups) varied with age.",Pharmacokinetics and pharmacodynamics of atracurium in infants and children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360737/),min,20.0,140675,DB00732,Atracurium besylate
,2360737,elimination half-life,"Neither elimination half-life (20.0 +/- 5.1, 17.2 +/- 5.1, and 15.7 +/- 2.5 min for the three groups) nor the steady state plasma concentration that resulted in 50% neuromuscular blockade (363 +/- 118, 444 +/- 121, and 436 +/- 122 ng/ml for the three groups) varied with age.",Pharmacokinetics and pharmacodynamics of atracurium in infants and children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360737/),min,17.2,140676,DB00732,Atracurium besylate
,2360737,elimination half-life,"Neither elimination half-life (20.0 +/- 5.1, 17.2 +/- 5.1, and 15.7 +/- 2.5 min for the three groups) nor the steady state plasma concentration that resulted in 50% neuromuscular blockade (363 +/- 118, 444 +/- 121, and 436 +/- 122 ng/ml for the three groups) varied with age.",Pharmacokinetics and pharmacodynamics of atracurium in infants and children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360737/),min,15.7,140677,DB00732,Atracurium besylate
,2360737,steady state plasma concentration,"Neither elimination half-life (20.0 +/- 5.1, 17.2 +/- 5.1, and 15.7 +/- 2.5 min for the three groups) nor the steady state plasma concentration that resulted in 50% neuromuscular blockade (363 +/- 118, 444 +/- 121, and 436 +/- 122 ng/ml for the three groups) varied with age.",Pharmacokinetics and pharmacodynamics of atracurium in infants and children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360737/),[ng] / [ml],363,140678,DB00732,Atracurium besylate
,2360737,steady state plasma concentration,"Neither elimination half-life (20.0 +/- 5.1, 17.2 +/- 5.1, and 15.7 +/- 2.5 min for the three groups) nor the steady state plasma concentration that resulted in 50% neuromuscular blockade (363 +/- 118, 444 +/- 121, and 436 +/- 122 ng/ml for the three groups) varied with age.",Pharmacokinetics and pharmacodynamics of atracurium in infants and children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360737/),[ng] / [ml],444,140679,DB00732,Atracurium besylate
,2360737,steady state plasma concentration,"Neither elimination half-life (20.0 +/- 5.1, 17.2 +/- 5.1, and 15.7 +/- 2.5 min for the three groups) nor the steady state plasma concentration that resulted in 50% neuromuscular blockade (363 +/- 118, 444 +/- 121, and 436 +/- 122 ng/ml for the three groups) varied with age.",Pharmacokinetics and pharmacodynamics of atracurium in infants and children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360737/),[ng] / [ml],436,140680,DB00732,Atracurium besylate
,1687880,low detection limit,The low detection limit of this method in the patient was 3 ng/mL.,Determination of vecuronium in blood by HPLC with UV and electrochemical detection: a pilot study in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687880/),[ng] / [ml],3,142308,DB00732,Atracurium besylate
,7913801,recovery time,"Atracurium's recovery time increased 2.4 +/- 2.2 min (mean +/- SD) with the larger dose, less than the increase with vecuronium (8.2 +/- 3.8 min).",Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913801/),min,2.4,144052,DB00732,Atracurium besylate
,7913801,recovery time,"Atracurium's recovery time increased 2.4 +/- 2.2 min (mean +/- SD) with the larger dose, less than the increase with vecuronium (8.2 +/- 3.8 min).",Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913801/),min,8.2,144053,DB00732,Atracurium besylate
,7913801,recovery phase half-life,Atracurium's recovery phase half-life was 14.6 +/- 1.7 and 20.1 +/- 2.3 min with the small and large doses (P < 0.05); vecuronium's recovery phase half-life increased similarly from 13.5 +/- 2.3 to 18.5 +/- 5.0 min (P < 0.05).,Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913801/),min,14.6,144054,DB00732,Atracurium besylate
,7913801,recovery phase half-life,Atracurium's recovery phase half-life was 14.6 +/- 1.7 and 20.1 +/- 2.3 min with the small and large doses (P < 0.05); vecuronium's recovery phase half-life increased similarly from 13.5 +/- 2.3 to 18.5 +/- 5.0 min (P < 0.05).,Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913801/),min,20.1,144055,DB00732,Atracurium besylate
,7913801,recovery phase half-life,Atracurium's recovery phase half-life was 14.6 +/- 1.7 and 20.1 +/- 2.3 min with the small and large doses (P < 0.05); vecuronium's recovery phase half-life increased similarly from 13.5 +/- 2.3 to 18.5 +/- 5.0 min (P < 0.05).,Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913801/),min,13.5,144056,DB00732,Atracurium besylate
,7913801,recovery phase half-life,Atracurium's recovery phase half-life was 14.6 +/- 1.7 and 20.1 +/- 2.3 min with the small and large doses (P < 0.05); vecuronium's recovery phase half-life increased similarly from 13.5 +/- 2.3 to 18.5 +/- 5.0 min (P < 0.05).,Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913801/),min,18.5,144057,DB00732,Atracurium besylate
,7913801,Ce,"At 75% recovery, vecuronium's Ce decreased from 65 +/- 18 ng/ml with the small dose to 55 +/- 15 ng/ml with the large dose (P < 0.05).",Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913801/),[ng] / [ml],65,144058,DB00732,Atracurium besylate
,7913801,Ce,"At 75% recovery, vecuronium's Ce decreased from 65 +/- 18 ng/ml with the small dose to 55 +/- 15 ng/ml with the large dose (P < 0.05).",Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913801/),[ng] / [ml],55,144059,DB00732,Atracurium besylate
,9806701,elimination rate constant,The elimination rate constant from the peripheral compartment was fixed to the in vitro rate of degradation of cisatracurium in human plasma (0.0237 min(-1)).,Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),1/[min],0.0237,145684,DB00732,Atracurium besylate
,9806701,rate of degradation,The elimination rate constant from the peripheral compartment was fixed to the in vitro rate of degradation of cisatracurium in human plasma (0.0237 min(-1)).,Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),1/[min],0.0237,145685,DB00732,Atracurium besylate
,9806701,terminal half-life,"The mean terminal half-life of cisatracurium was 23.9+/-3.3 min, and its total clearance averaged 3.7+/-0.8 mL x min(-1) x kg(-1).",Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),min,23.9,145686,DB00732,Atracurium besylate
,9806701,total clearance,"The mean terminal half-life of cisatracurium was 23.9+/-3.3 min, and its total clearance averaged 3.7+/-0.8 mL x min(-1) x kg(-1).",Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),[ml] / [kg·min],3.7,145687,DB00732,Atracurium besylate
,9806701,volume of distribution at steady state,"Using this model, the volume of distribution at steady state was significantly increased compared with that obtained when central elimination only was assumed (0.118+/-0.027 vs 0.089+/-0.017 L/kg).",Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),[l] / [kg],0.118,145688,DB00732,Atracurium besylate
,9806701,volume of distribution at steady state,"Using this model, the volume of distribution at steady state was significantly increased compared with that obtained when central elimination only was assumed (0.118+/-0.027 vs 0.089+/-0.017 L/kg).",Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),[l] / [kg],0.089,145689,DB00732,Atracurium besylate
,9806701,rate constant,The effect-plasma equilibration rate constant was 0.054+/-0.013 min(-1).,Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),1/[min],0.054,145690,DB00732,Atracurium besylate
,9806701,50% effective concentration,"The 50% effective concentration (153+/-33 ng/mL) was 56% higher than that reported in patients anesthetized with volatile anesthetics, which suggests that, compared with inhaled anesthetics, a cisatracurium neuromuscular block is less enhanced by propofol.",Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),[ng] / [ml],153,145691,DB00732,Atracurium besylate
,6688015,EC50,Good correlation between plasma concentration and response for all patients gave an EC50 of 0.29 +/- 0.04 (SD) microgram ml-1 and a Hill coefficient of 4.6 +/- 0.5 (SD).,Combined pharmacokinetic and pharmacodynamic study of a single bolus dose of atracurium. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688015/),[μg] / [ml],0.29,146927,DB00732,Atracurium besylate
,6688015,Hill coefficient,Good correlation between plasma concentration and response for all patients gave an EC50 of 0.29 +/- 0.04 (SD) microgram ml-1 and a Hill coefficient of 4.6 +/- 0.5 (SD).,Combined pharmacokinetic and pharmacodynamic study of a single bolus dose of atracurium. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688015/),,4.6,146928,DB00732,Atracurium besylate
,2265055,rate of infusion,The total dose of atracurium given was 14.3-136.6 mg kg-1; rate of infusion was 0.6-1.38 mg kg-1 h-1.,Concentrations of atracurium and laudanosine in cerebrospinal fluid and plasma in three intensive care patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265055/),[mg] / [h·kg],0.6-1.38,150014,DB00732,Atracurium besylate
,2265055,Plasma concentrations,"Plasma concentrations of atracurium and laudanosine were 0.73-3.11 micrograms ml-1 and 0.48-8.65 micrograms ml-1, respectively; CSF concentration of laudanosine was 70-440 ng ml-1.",Concentrations of atracurium and laudanosine in cerebrospinal fluid and plasma in three intensive care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265055/),[μg] / [ml],0.73-3.11,150015,DB00732,Atracurium besylate
,2265055,Plasma concentrations,"Plasma concentrations of atracurium and laudanosine were 0.73-3.11 micrograms ml-1 and 0.48-8.65 micrograms ml-1, respectively; CSF concentration of laudanosine was 70-440 ng ml-1.",Concentrations of atracurium and laudanosine in cerebrospinal fluid and plasma in three intensive care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265055/),[μg] / [ml],0.48-8.65,150016,DB00732,Atracurium besylate
,2265055,CSF concentration,"Plasma concentrations of atracurium and laudanosine were 0.73-3.11 micrograms ml-1 and 0.48-8.65 micrograms ml-1, respectively; CSF concentration of laudanosine was 70-440 ng ml-1.",Concentrations of atracurium and laudanosine in cerebrospinal fluid and plasma in three intensive care patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265055/),[ng] / [ml],70-440,150017,DB00732,Atracurium besylate
,2932981,steady state plasma concentrations,"These estimates were used to determine the rates of infusion that would produce steady state plasma concentrations of laudanosine of approximately 200, 400, and 800 ng . ml-1.",Laudanosine (a metabolite of atracurium) increases the minimum alveolar concentration of halothane in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2932981/),[ng] / [ml],200,150564,DB00732,Atracurium besylate
,2932981,steady state plasma concentrations,"These estimates were used to determine the rates of infusion that would produce steady state plasma concentrations of laudanosine of approximately 200, 400, and 800 ng . ml-1.",Laudanosine (a metabolite of atracurium) increases the minimum alveolar concentration of halothane in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2932981/),[ng] / [ml],400,150565,DB00732,Atracurium besylate
,2932981,steady state plasma concentrations,"These estimates were used to determine the rates of infusion that would produce steady state plasma concentrations of laudanosine of approximately 200, 400, and 800 ng . ml-1.",Laudanosine (a metabolite of atracurium) increases the minimum alveolar concentration of halothane in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2932981/),[ng] / [ml],800,150566,DB00732,Atracurium besylate
,2932981,steady state plasma concentrations,"Subsequent infusion of laudanosine in eight rabbits produced mean (+/- SD) steady state plasma concentrations of laudanosine of 234 +/- 56, 457 +/- 66, and 873 +/- 105 ng . ml-1.",Laudanosine (a metabolite of atracurium) increases the minimum alveolar concentration of halothane in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2932981/),[ng] / [ml],234,150567,DB00732,Atracurium besylate
,2932981,steady state plasma concentrations,"Subsequent infusion of laudanosine in eight rabbits produced mean (+/- SD) steady state plasma concentrations of laudanosine of 234 +/- 56, 457 +/- 66, and 873 +/- 105 ng . ml-1.",Laudanosine (a metabolite of atracurium) increases the minimum alveolar concentration of halothane in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2932981/),[ng] / [ml],457,150568,DB00732,Atracurium besylate
,2932981,steady state plasma concentrations,"Subsequent infusion of laudanosine in eight rabbits produced mean (+/- SD) steady state plasma concentrations of laudanosine of 234 +/- 56, 457 +/- 66, and 873 +/- 105 ng . ml-1.",Laudanosine (a metabolite of atracurium) increases the minimum alveolar concentration of halothane in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2932981/),[ng] / [ml],873,150569,DB00732,Atracurium besylate
,2932981,MAC,The control value for MAC of halothane was 1.08 +/- 0.28%.,Laudanosine (a metabolite of atracurium) increases the minimum alveolar concentration of halothane in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2932981/),%,1,150570,DB00732,Atracurium besylate
,23698546,Central,"Central and steady state apparent volumes of distribution (V1, Vdss) and slope factor (γ) were larger, effect-compartment concentration at 50% neuromuscular block was lower in the ANH (90.8±41.6 mL kg-1, 159.1±39.2 mL kg-1, 6.0±0.9 and 136.4±29.1 ng·mL-1) compared with the control group (65.5±26.1 mL kg-1, 134.8±31.8 mL kg-1, 5.5±0.8 and 158.5±26.0 ng·mL-1) respectively.",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),[ml] / [kg],90.8,151983,DB00732,Atracurium besylate
,23698546,"steady state apparent volumes of distribution (V1, Vdss)","Central and steady state apparent volumes of distribution (V1, Vdss) and slope factor (γ) were larger, effect-compartment concentration at 50% neuromuscular block was lower in the ANH (90.8±41.6 mL kg-1, 159.1±39.2 mL kg-1, 6.0±0.9 and 136.4±29.1 ng·mL-1) compared with the control group (65.5±26.1 mL kg-1, 134.8±31.8 mL kg-1, 5.5±0.8 and 158.5±26.0 ng·mL-1) respectively.",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),[ml] / [kg],159.1,151984,DB00732,Atracurium besylate
,23698546,"steady state apparent volumes of distribution (V1, Vdss)","Central and steady state apparent volumes of distribution (V1, Vdss) and slope factor (γ) were larger, effect-compartment concentration at 50% neuromuscular block was lower in the ANH (90.8±41.6 mL kg-1, 159.1±39.2 mL kg-1, 6.0±0.9 and 136.4±29.1 ng·mL-1) compared with the control group (65.5±26.1 mL kg-1, 134.8±31.8 mL kg-1, 5.5±0.8 and 158.5±26.0 ng·mL-1) respectively.",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),[ng] / [ml],6.0,151985,DB00732,Atracurium besylate
,23698546,"steady state apparent volumes of distribution (V1, Vdss)","Central and steady state apparent volumes of distribution (V1, Vdss) and slope factor (γ) were larger, effect-compartment concentration at 50% neuromuscular block was lower in the ANH (90.8±41.6 mL kg-1, 159.1±39.2 mL kg-1, 6.0±0.9 and 136.4±29.1 ng·mL-1) compared with the control group (65.5±26.1 mL kg-1, 134.8±31.8 mL kg-1, 5.5±0.8 and 158.5±26.0 ng·mL-1) respectively.",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),[ml] / [kg],134.8,151986,DB00732,Atracurium besylate
,23698546,slope factor (γ),"Central and steady state apparent volumes of distribution (V1, Vdss) and slope factor (γ) were larger, effect-compartment concentration at 50% neuromuscular block was lower in the ANH (90.8±41.6 mL kg-1, 159.1±39.2 mL kg-1, 6.0±0.9 and 136.4±29.1 ng·mL-1) compared with the control group (65.5±26.1 mL kg-1, 134.8±31.8 mL kg-1, 5.5±0.8 and 158.5±26.0 ng·mL-1) respectively.",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),[ml] / [kg],134.8,151987,DB00732,Atracurium besylate
,23698546,Elimination half-life (t1/2 β),"Elimination half-life (t1/2 β) and mean residence time (MRT) were longer in the ANH (37.2±20.9, 23.5±13.2 min) than the control group (26.8±9.8, 16.9±6.2 min), albeit not statistically significant (P=0.051, P=0.051).",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),min,37.2,151988,DB00732,Atracurium besylate
,23698546,Elimination half-life (t1/2 β),"Elimination half-life (t1/2 β) and mean residence time (MRT) were longer in the ANH (37.2±20.9, 23.5±13.2 min) than the control group (26.8±9.8, 16.9±6.2 min), albeit not statistically significant (P=0.051, P=0.051).",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),min,26.8,151989,DB00732,Atracurium besylate
,23698546,mean residence time (MRT),"Elimination half-life (t1/2 β) and mean residence time (MRT) were longer in the ANH (37.2±20.9, 23.5±13.2 min) than the control group (26.8±9.8, 16.9±6.2 min), albeit not statistically significant (P=0.051, P=0.051).",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),min,23.5,151990,DB00732,Atracurium besylate
,23698546,mean residence time (MRT),"Elimination half-life (t1/2 β) and mean residence time (MRT) were longer in the ANH (37.2±20.9, 23.5±13.2 min) than the control group (26.8±9.8, 16.9±6.2 min), albeit not statistically significant (P=0.051, P=0.051).",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),min,26.8,151991,DB00732,Atracurium besylate
,23698546,mean residence time (MRT),"Elimination half-life (t1/2 β) and mean residence time (MRT) were longer in the ANH (37.2±20.9, 23.5±13.2 min) than the control group (26.8±9.8, 16.9±6.2 min), albeit not statistically significant (P=0.051, P=0.051).",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),min,16.9,151992,DB00732,Atracurium besylate
,23698546,distribution half-life (t1/2 α),"There were no significant differences in distribution half-life (t1/2 α), effect-compartment equilibration rate-constant (keo), central and total clearances (Clc, Cl) between the ANH (2.4±1.2 min, 0.070±0.013 min-1, 6.1±1.9 mL kg-1 min-1 and 7.7±2.3 mL kg-1 min-1) and control group (1.9±1.2 min, 0.063±0.008 min-1, 7.0±1.8 mL kg-1 min-1 and 8.5±2.1 mL kg-1 min-1) respectively.",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),min,2.4,151993,DB00732,Atracurium besylate
,23698546,"total clearances (Clc, Cl)","There were no significant differences in distribution half-life (t1/2 α), effect-compartment equilibration rate-constant (keo), central and total clearances (Clc, Cl) between the ANH (2.4±1.2 min, 0.070±0.013 min-1, 6.1±1.9 mL kg-1 min-1 and 7.7±2.3 mL kg-1 min-1) and control group (1.9±1.2 min, 0.063±0.008 min-1, 7.0±1.8 mL kg-1 min-1 and 8.5±2.1 mL kg-1 min-1) respectively.",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),[ml] / [kg·min],6.1,151994,DB00732,Atracurium besylate
,23698546,"total clearances (Clc, Cl)","There were no significant differences in distribution half-life (t1/2 α), effect-compartment equilibration rate-constant (keo), central and total clearances (Clc, Cl) between the ANH (2.4±1.2 min, 0.070±0.013 min-1, 6.1±1.9 mL kg-1 min-1 and 7.7±2.3 mL kg-1 min-1) and control group (1.9±1.2 min, 0.063±0.008 min-1, 7.0±1.8 mL kg-1 min-1 and 8.5±2.1 mL kg-1 min-1) respectively.",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),[ml] / [kg·min],7.7,151995,DB00732,Atracurium besylate
,11732518,maximum infusion rate during steady-state conditions,The mean (range) maximum infusion rate during steady-state conditions was 1.44 (0.48-3.13) mg kg(-1) h(-1) and the duration of infusion 36.9 (22.5-98.4) h.,Pharmacokinetics and dynamics of atracurium infusions after paediatric orthotopic liver transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11732518/),[mg] / [h·kg],1.44,157882,DB00732,Atracurium besylate
,11732518,duration of infusion,The mean (range) maximum infusion rate during steady-state conditions was 1.44 (0.48-3.13) mg kg(-1) h(-1) and the duration of infusion 36.9 (22.5-98.4) h.,Pharmacokinetics and dynamics of atracurium infusions after paediatric orthotopic liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11732518/),h,36.9,157883,DB00732,Atracurium besylate
,11732518,terminal half-life (t1/2),The mean terminal half-life (t1/2) for atracurium was 18.8 (12-32.3) min.,Pharmacokinetics and dynamics of atracurium infusions after paediatric orthotopic liver transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11732518/),min,18.8,157884,DB00732,Atracurium besylate
,11732518,steady-state plasma clearance (CLss),The steady-state plasma clearance (CLss) was 13.9 (7.9-20.3) ml min(-1) kg(-1) and the terminal volume of distribution (Vz) 390 (124-551) ml kg(-1); both were higher than in adults after successful OLT.,Pharmacokinetics and dynamics of atracurium infusions after paediatric orthotopic liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11732518/),[ml] / [kg·min],13.9,157885,DB00732,Atracurium besylate
,11732518,terminal volume of distribution (Vz),The steady-state plasma clearance (CLss) was 13.9 (7.9-20.3) ml min(-1) kg(-1) and the terminal volume of distribution (Vz) 390 (124-551) ml kg(-1); both were higher than in adults after successful OLT.,Pharmacokinetics and dynamics of atracurium infusions after paediatric orthotopic liver transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11732518/),[ml] / [kg],390,157886,DB00732,Atracurium besylate
,11732518,maximum concentration (Cmax),The maximum concentration (Cmax) of laudanosine was 1190 (400-1890) ng ml(-1) and t1/2 was 3.9 (1.1-6.7) h.,Pharmacokinetics and dynamics of atracurium infusions after paediatric orthotopic liver transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11732518/),[ng] / [ml],1190,157887,DB00732,Atracurium besylate
,11732518,t1/2,The maximum concentration (Cmax) of laudanosine was 1190 (400-1890) ng ml(-1) and t1/2 was 3.9 (1.1-6.7) h.,Pharmacokinetics and dynamics of atracurium infusions after paediatric orthotopic liver transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11732518/),h,3.9,157888,DB00732,Atracurium besylate
,11732518,renal clearance,"The renal clearance of laudanosine was 0.9 (0.1-2.5) ml min(-1) kg(-1) and increased with urine flow, but there was no significant relationship with serum creatinine.",Pharmacokinetics and dynamics of atracurium infusions after paediatric orthotopic liver transplantation. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11732518/),[ml] / [kg·min],0.9,157889,DB00732,Atracurium besylate
,11732518,Cmax,EEG spikes were confirmed in one child only; the corresponding laudanosine Cmax was 720 ng ml(-1).,Pharmacokinetics and dynamics of atracurium infusions after paediatric orthotopic liver transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11732518/),[ng] / [ml],720,157890,DB00732,Atracurium besylate
,11732518,Cmax,Monoquaternary alcohol Cmax was 986 (330-1770) ng ml(-1) and t1/2 42.9 (30-57.7) min.,Pharmacokinetics and dynamics of atracurium infusions after paediatric orthotopic liver transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11732518/),[ng] / [ml],986,157891,DB00732,Atracurium besylate
,11732518,t1/2,Monoquaternary alcohol Cmax was 986 (330-1770) ng ml(-1) and t1/2 42.9 (30-57.7) min.,Pharmacokinetics and dynamics of atracurium infusions after paediatric orthotopic liver transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11732518/),min,42.9,157892,DB00732,Atracurium besylate
>,11732518,recovery time,Mean recovery time on stopping the atracurium infusion to a TOF ratio >0.75 was 23.6 (12-27) min.,Pharmacokinetics and dynamics of atracurium infusions after paediatric orthotopic liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11732518/),min,0.75,157893,DB00732,Atracurium besylate
>,11732518,recovery time,Mean recovery time on stopping the atracurium infusion to a TOF ratio >0.75 was 23.6 (12-27) min.,Pharmacokinetics and dynamics of atracurium infusions after paediatric orthotopic liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11732518/),min,23.6,157894,DB00732,Atracurium besylate
>,11732518,TOF ratio,Mean recovery time on stopping the atracurium infusion to a TOF ratio >0.75 was 23.6 (12-27) min.,Pharmacokinetics and dynamics of atracurium infusions after paediatric orthotopic liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11732518/),min,0.75,157895,DB00732,Atracurium besylate
>,11732518,TOF ratio,Mean recovery time on stopping the atracurium infusion to a TOF ratio >0.75 was 23.6 (12-27) min.,Pharmacokinetics and dynamics of atracurium infusions after paediatric orthotopic liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11732518/),min,23.6,157896,DB00732,Atracurium besylate
,8915441,T1,The infusion was discontinued and 50 to 75% T1 recovery time was recorded.,"Pharmacokinetics, effects on renal function, and potentiation of atracurium-induced neuromuscular blockade after administration of a high dose of gentamicin in isoflurane-anesthetized dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8915441/),%,50 to 75,162130,DB00732,Atracurium besylate
,8915441,volume of distribution,"Mean values for volume of distribution and clearance were 0.263 L/kg and 2.0 ml/min/kg, respectively.","Pharmacokinetics, effects on renal function, and potentiation of atracurium-induced neuromuscular blockade after administration of a high dose of gentamicin in isoflurane-anesthetized dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8915441/),[l] / [kg],0.263,162131,DB00732,Atracurium besylate
,8915441,clearance,"Mean values for volume of distribution and clearance were 0.263 L/kg and 2.0 ml/min/kg, respectively.","Pharmacokinetics, effects on renal function, and potentiation of atracurium-induced neuromuscular blockade after administration of a high dose of gentamicin in isoflurane-anesthetized dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8915441/),[ml] / [kg·min],2.0,162132,DB00732,Atracurium besylate
,8915441,maximal serum concentration,Mean maximal serum concentration of gentamicin was 46.4 micrograms/ml.,"Pharmacokinetics, effects on renal function, and potentiation of atracurium-induced neuromuscular blockade after administration of a high dose of gentamicin in isoflurane-anesthetized dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8915441/),[μg] / [ml],46.4,162133,DB00732,Atracurium besylate
,2302373,T beta s1/2,"The two methods utilizing effect data alone yielded values of 4.2 (0.7) min and 4.3 (0.5) min (mean (SEM)), respectively, for T beta s1/2 compared with 4.1 (0.6) min when the constant was calculated using plasma concentration data for T beta 1/2 and curve fitting to the concentration-effect data to determine s.",A simplified approach to the effect kinetics of atracurium. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2302373/),min,4.3,166398,DB00732,Atracurium besylate
,2611066,elimination half-life (T1/2 beta),"The elimination half-life (T1/2 beta) of atracurium was significantly longer in the elderly group (23.1 v. 20.1 min), but there was no significant difference between the two groups in clearance (Cl), the volume of distribution (V beta) or the mean residence time (MRT) of atracurium.",Pharmacokinetics of atracurium and laudanosine in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611066/),min,23.1,168178,DB00732,Atracurium besylate
,2611066,elimination half-life (T1/2 beta),"The elimination half-life (T1/2 beta) of atracurium was significantly longer in the elderly group (23.1 v. 20.1 min), but there was no significant difference between the two groups in clearance (Cl), the volume of distribution (V beta) or the mean residence time (MRT) of atracurium.",Pharmacokinetics of atracurium and laudanosine in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611066/),min,20.1,168179,DB00732,Atracurium besylate
,2611066,T1/2 beta,Laudanosine T1/2 beta was also significantly longer (229.1 v. 173.1 min) and the clearance significantly slower (4.85 v. 7.29 ml min-1 kg-1) in the elderly.,Pharmacokinetics of atracurium and laudanosine in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611066/),min,229.1,168180,DB00732,Atracurium besylate
,2611066,T1/2 beta,Laudanosine T1/2 beta was also significantly longer (229.1 v. 173.1 min) and the clearance significantly slower (4.85 v. 7.29 ml min-1 kg-1) in the elderly.,Pharmacokinetics of atracurium and laudanosine in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611066/),min,173.1,168181,DB00732,Atracurium besylate
,2611066,clearance,Laudanosine T1/2 beta was also significantly longer (229.1 v. 173.1 min) and the clearance significantly slower (4.85 v. 7.29 ml min-1 kg-1) in the elderly.,Pharmacokinetics of atracurium and laudanosine in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611066/),[ml] / [kg·min],4.85,168182,DB00732,Atracurium besylate
,2611066,clearance,Laudanosine T1/2 beta was also significantly longer (229.1 v. 173.1 min) and the clearance significantly slower (4.85 v. 7.29 ml min-1 kg-1) in the elderly.,Pharmacokinetics of atracurium and laudanosine in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611066/),[ml] / [kg·min],7.29,168183,DB00732,Atracurium besylate
,1928855,central compartment volume,"The AIH only altered the central compartment volume (65.5 +/- 15.6 l in the control group vs 83.6 +/- 13.3 l in group II, p less than 0.01).",[Pharmacokinetics of propofol injected after deliberate preoperative hemodilution]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1928855/),l,65.5,171206,DB00732,Atracurium besylate
,1928855,central compartment volume,"The AIH only altered the central compartment volume (65.5 +/- 15.6 l in the control group vs 83.6 +/- 13.3 l in group II, p less than 0.01).",[Pharmacokinetics of propofol injected after deliberate preoperative hemodilution]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1928855/),l,83.6,171207,DB00732,Atracurium besylate
,1928855,Initial concentrations,"Initial concentrations were not significantly different in the two groups (2,892 +/- 762 ng.ml-1 in controls vs 2,373 +/- 589 ng.ml-1 in the others).",[Pharmacokinetics of propofol injected after deliberate preoperative hemodilution]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1928855/),[ng] / [ml],"2,892",171208,DB00732,Atracurium besylate
,1928855,Initial concentrations,"Initial concentrations were not significantly different in the two groups (2,892 +/- 762 ng.ml-1 in controls vs 2,373 +/- 589 ng.ml-1 in the others).",[Pharmacokinetics of propofol injected after deliberate preoperative hemodilution]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1928855/),[ng] / [ml],"2,373",171209,DB00732,Atracurium besylate
,3674472,half-lives,"In buffered saline, pH 7.4, at 37 degrees C, the half-lives of the three isomer groups were 57.1 +/- 0.9, 59.7 +/- 0.9, and 66.4 +/- 2.7 min, respectively, for the cis-cis, cis-trans, and trans-trans groups.",The pharmacokinetics of atracurium isomers in vitro and in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3674472/),min,57.1,183254,DB00732,Atracurium besylate
,3674472,half-lives,"In buffered saline, pH 7.4, at 37 degrees C, the half-lives of the three isomer groups were 57.1 +/- 0.9, 59.7 +/- 0.9, and 66.4 +/- 2.7 min, respectively, for the cis-cis, cis-trans, and trans-trans groups.",The pharmacokinetics of atracurium isomers in vitro and in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3674472/),min,59.7,183255,DB00732,Atracurium besylate
,3674472,half-lives,"In buffered saline, pH 7.4, at 37 degrees C, the half-lives of the three isomer groups were 57.1 +/- 0.9, 59.7 +/- 0.9, and 66.4 +/- 2.7 min, respectively, for the cis-cis, cis-trans, and trans-trans groups.",The pharmacokinetics of atracurium isomers in vitro and in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3674472/),min,66.4,183256,DB00732,Atracurium besylate
,3674472,half-life,The cis-cis group broke down in a monoexponential manner with a half-life of 23.3 +/- 2.8 min.,The pharmacokinetics of atracurium isomers in vitro and in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3674472/),min,23.3,183257,DB00732,Atracurium besylate
,3674472,rapid phase,The cis-trans group showed bi-exponential breakdown with a rapid phase of 2.3 +/- 0.4 min and a slow phase of 22.1 +/- 2.9 min.,The pharmacokinetics of atracurium isomers in vitro and in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3674472/),min,2.3,183258,DB00732,Atracurium besylate
,3674472,slow phase,The cis-trans group showed bi-exponential breakdown with a rapid phase of 2.3 +/- 0.4 min and a slow phase of 22.1 +/- 2.9 min.,The pharmacokinetics of atracurium isomers in vitro and in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3674472/),min,22.1,183259,DB00732,Atracurium besylate
,3674472,elimination half-life,"In eight patients, the mean elimination half-life and apparent clearance of the cis-cis group were 20.6 +/- 1.5 min and 5.3 +/- 0.4 ml.kg-1.min-1, respectively.",The pharmacokinetics of atracurium isomers in vitro and in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3674472/),min,20.6,183260,DB00732,Atracurium besylate
,3674472,apparent clearance,"In eight patients, the mean elimination half-life and apparent clearance of the cis-cis group were 20.6 +/- 1.5 min and 5.3 +/- 0.4 ml.kg-1.min-1, respectively.",The pharmacokinetics of atracurium isomers in vitro and in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3674472/),[ml] / [kg·min],5.3,183261,DB00732,Atracurium besylate
,3674472,apparent elimination half-life,"For the cis-trans group, the apparent elimination half-life and clearance were 17.7 +/- 1.8 min and 9.0 +/- 1.0 ml.kg-1.min-1, but these figures require care in interpretation, as this isomer group contains isomers of widely varying rates of decomposition.",The pharmacokinetics of atracurium isomers in vitro and in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3674472/),min,17.7,183262,DB00732,Atracurium besylate
,3674472,clearance,"For the cis-trans group, the apparent elimination half-life and clearance were 17.7 +/- 1.8 min and 9.0 +/- 1.0 ml.kg-1.min-1, but these figures require care in interpretation, as this isomer group contains isomers of widely varying rates of decomposition.",The pharmacokinetics of atracurium isomers in vitro and in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3674472/),[ml] / [kg·min],9.0,183263,DB00732,Atracurium besylate
,10069275,Total sufen,Total sufentanil dose was 773 +/- 186 microg in the continuous-infusion group and 610 +/- 184 microg in the bolus group (p = 0.01).,Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),μg,773,186592,DB00732,Atracurium besylate
,10069275,dose,Total sufentanil dose was 773 +/- 186 microg in the continuous-infusion group and 610 +/- 184 microg in the bolus group (p = 0.01).,Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),μg,773,186593,DB00732,Atracurium besylate
,10069275,dose,Total sufentanil dose was 773 +/- 186 microg in the continuous-infusion group and 610 +/- 184 microg in the bolus group (p = 0.01).,Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),μ,610,186594,DB00732,Atracurium besylate
,10069275,Total midazolam dose,"Total midazolam dose was 14.4 +/- 3 mg and 11.2 +/- 3 mg in the continuous-infusion and bolus groups, respectively.",Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),mg,14.4,186595,DB00732,Atracurium besylate
,10069275,Total midazolam dose,"Total midazolam dose was 14.4 +/- 3 mg and 11.2 +/- 3 mg in the continuous-infusion and bolus groups, respectively.",Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),mg,11.2,186596,DB00732,Atracurium besylate
,10069275,Plasma,Plasma sufentanil concentrations at extubation were similar in both groups (0.5 ng/mL).,Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),[ng] / [ml],0.5,186597,DB00732,Atracurium besylate
,10069275,Plasma midazolam concentrations,Plasma midazolam concentrations at extubation in the bolus group (17 +/- 6.7 ng/mL) were similar to those in the continuous-infusion group (23 +/- 5 ng/mL).,Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),[ng] / [ml],17,186598,DB00732,Atracurium besylate
,10069275,Plasma midazolam concentrations,Plasma midazolam concentrations at extubation in the bolus group (17 +/- 6.7 ng/mL) were similar to those in the continuous-infusion group (23 +/- 5 ng/mL).,Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),[ng] / [ml],23,186599,DB00732,Atracurium besylate
,6239574,peak levels,There were measurable levels of laudanosine following atracurium administration with peak levels of 199 +/- 31 ng . ml-1 at 2 min.,The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6239574/),[ng] / [ml],199,187849,DB00732,Atracurium besylate
,8533555,elimination half-life,The elimination half-life of 51W89 was significantly longer in renal failure patients than in healthy controls (38.9 min vs 30.6 min; P < 0.05).,Pharmacokinetics of 51W89: preliminary data. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533555/),min,38.9,188117,DB00732,Atracurium besylate
,8533555,elimination half-life,The elimination half-life of 51W89 was significantly longer in renal failure patients than in healthy controls (38.9 min vs 30.6 min; P < 0.05).,Pharmacokinetics of 51W89: preliminary data. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533555/),min,30.6,188118,DB00732,Atracurium besylate
,11506100,effect compartment concentration at 50% block (EC50),"With the parametric approach, the effect compartment concentration at 50% block (EC50) significantly increased with the dose (136 vs. 157 vs. 209 ng/ml), whereas the effect compartment equilibration rate constant decreased (0.0675 vs. 0.0568 vs. 0.0478 min(-1)).",Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506100/),[ng] / [ml],136,191220,DB00732,Atracurium besylate
,11506100,effect compartment concentration at 50% block (EC50),"With the parametric approach, the effect compartment concentration at 50% block (EC50) significantly increased with the dose (136 vs. 157 vs. 209 ng/ml), whereas the effect compartment equilibration rate constant decreased (0.0675 vs. 0.0568 vs. 0.0478 min(-1)).",Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506100/),[ng] / [ml],157,191221,DB00732,Atracurium besylate
,11506100,effect compartment concentration at 50% block (EC50),"With the parametric approach, the effect compartment concentration at 50% block (EC50) significantly increased with the dose (136 vs. 157 vs. 209 ng/ml), whereas the effect compartment equilibration rate constant decreased (0.0675 vs. 0.0568 vs. 0.0478 min(-1)).",Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506100/),[ng] / [ml],209,191222,DB00732,Atracurium besylate
,11506100,rate constant,"With the parametric approach, the effect compartment concentration at 50% block (EC50) significantly increased with the dose (136 vs. 157 vs. 209 ng/ml), whereas the effect compartment equilibration rate constant decreased (0.0675 vs. 0.0568 vs. 0.0478 min(-1)).",Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506100/),1/[min],0.0675,191223,DB00732,Atracurium besylate
,11506100,rate constant,"With the parametric approach, the effect compartment concentration at 50% block (EC50) significantly increased with the dose (136 vs. 157 vs. 209 ng/ml), whereas the effect compartment equilibration rate constant decreased (0.0675 vs. 0.0568 vs. 0.0478 min(-1)).",Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506100/),1/[min],0.0568,191224,DB00732,Atracurium besylate
,11506100,rate constant,"With the parametric approach, the effect compartment concentration at 50% block (EC50) significantly increased with the dose (136 vs. 157 vs. 209 ng/ml), whereas the effect compartment equilibration rate constant decreased (0.0675 vs. 0.0568 vs. 0.0478 min(-1)).",Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506100/),1/[min],0.0478,191225,DB00732,Atracurium besylate
,16492821,Onset time,"Onset time was 2.5 +/- 0.8 min, recovery to 25% of baseline twitch height was 37.6 +/- 10.2 min, and the 25%-75% recovery index was 10.9 +/- 3.7 min.",Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),min,2.5,197103,DB00732,Atracurium besylate
,16492821,recovery to 25% of baseline twitch height,"Onset time was 2.5 +/- 0.8 min, recovery to 25% of baseline twitch height was 37.6 +/- 10.2 min, and the 25%-75% recovery index was 10.9 +/- 3.7 min.",Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),min,37.6,197104,DB00732,Atracurium besylate
,16492821,25%-75% recovery index,"Onset time was 2.5 +/- 0.8 min, recovery to 25% of baseline twitch height was 37.6 +/- 10.2 min, and the 25%-75% recovery index was 10.9 +/- 3.7 min.",Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),min,10.9,197105,DB00732,Atracurium besylate
,16492821,Distribution,"Distribution and elimination half-lives were 3.5 +/- 0.9 min and 22.9 +/- 4.5 min, respectively.",Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),min,3.5,197106,DB00732,Atracurium besylate
,16492821,elimination half-lives,"Distribution and elimination half-lives were 3.5 +/- 0.9 min and 22.9 +/- 4.5 min, respectively.",Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),min,22.9,197107,DB00732,Atracurium besylate
,16492821,Steady-state volume of distribution,Steady-state volume of distribution (0.207 +/- 0.031 L/kg) and total body clearance (6.8 +/- 0.7 mL/min/kg) were significantly larger than those published for adults.,Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),[l] / [kg],0.207,197108,DB00732,Atracurium besylate
,16492821,total body clearance,Steady-state volume of distribution (0.207 +/- 0.031 L/kg) and total body clearance (6.8 +/- 0.7 mL/min/kg) were significantly larger than those published for adults.,Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),[ml] / [kg·min],6.8,197109,DB00732,Atracurium besylate
,16492821,rate constant,"Although the plasma-effect compartment equilibration rate constant was twofold faster (0.115 +/- 0.025 min(-1)) than that published for cisatracurium in adults, the effect compartment concentration corresponding to 50% block was similar (129 +/- 27 ng/mL).",Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),1/[min],0.115,197110,DB00732,Atracurium besylate
,15236083,t(1/2Alpha),"When the plasma concentrations of atracurium were determined in 2 clinical cases, t(1/2Alpha) was 2.10 and 1.73 min and t(1/2Beta) was 15.57 and 21.57 min, respectively.",Quantitative determination of atracurium in human plasma using high-performance liquid chromatography. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15236083/),min,2.10,207245,DB00732,Atracurium besylate
,15236083,t(1/2Alpha),"When the plasma concentrations of atracurium were determined in 2 clinical cases, t(1/2Alpha) was 2.10 and 1.73 min and t(1/2Beta) was 15.57 and 21.57 min, respectively.",Quantitative determination of atracurium in human plasma using high-performance liquid chromatography. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15236083/),min,1.73,207246,DB00732,Atracurium besylate
,15236083,t(1/2Beta),"When the plasma concentrations of atracurium were determined in 2 clinical cases, t(1/2Alpha) was 2.10 and 1.73 min and t(1/2Beta) was 15.57 and 21.57 min, respectively.",Quantitative determination of atracurium in human plasma using high-performance liquid chromatography. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15236083/),min,15.57,207247,DB00732,Atracurium besylate
,15236083,t(1/2Beta),"When the plasma concentrations of atracurium were determined in 2 clinical cases, t(1/2Alpha) was 2.10 and 1.73 min and t(1/2Beta) was 15.57 and 21.57 min, respectively.",Quantitative determination of atracurium in human plasma using high-performance liquid chromatography. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15236083/),min,21.57,207248,DB00732,Atracurium besylate
,10225075,"noncompartmental clearance (Cl, 1/min)","No difference between groups with respect to the primary outcome variable noncompartmental clearance (Cl, 1/min) 1.7 vs 1.6, was found.",Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225075/),,1.7,208640,DB00732,Atracurium besylate
,10225075,"noncompartmental clearance (Cl, 1/min)","No difference between groups with respect to the primary outcome variable noncompartmental clearance (Cl, 1/min) 1.7 vs 1.6, was found.",Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225075/),,1.6,208641,DB00732,Atracurium besylate
,10225075,"volume of distribution at steady state (Vss,","However, the volume of distribution at steady state (Vss, 1/kg) was larger in women (3.1) compared to men (1.3).",Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225075/),[1] / [kg],3.1,208642,DB00732,Atracurium besylate
,10225075,"volume of distribution at steady state (Vss,","However, the volume of distribution at steady state (Vss, 1/kg) was larger in women (3.1) compared to men (1.3).",Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225075/),[1] / [kg],1.3,208643,DB00732,Atracurium besylate
,10225075,half-lives,"The half-lives (min) of the alpha, beta and gamma phases (men vs women, medians) were 1.5 vs 2.2, 42 vs 40 and 222 vs 360, respectively.",Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225075/),min,1.5,208644,DB00732,Atracurium besylate
,10225075,half-lives,"The half-lives (min) of the alpha, beta and gamma phases (men vs women, medians) were 1.5 vs 2.2, 42 vs 40 and 222 vs 360, respectively.",Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225075/),min,2.2,208645,DB00732,Atracurium besylate
,10225075,half-lives,"The half-lives (min) of the alpha, beta and gamma phases (men vs women, medians) were 1.5 vs 2.2, 42 vs 40 and 222 vs 360, respectively.",Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225075/),min,42,208646,DB00732,Atracurium besylate
,10225075,half-lives,"The half-lives (min) of the alpha, beta and gamma phases (men vs women, medians) were 1.5 vs 2.2, 42 vs 40 and 222 vs 360, respectively.",Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225075/),min,40,208647,DB00732,Atracurium besylate
,10225075,half-lives,"The half-lives (min) of the alpha, beta and gamma phases (men vs women, medians) were 1.5 vs 2.2, 42 vs 40 and 222 vs 360, respectively.",Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225075/),min,222,208648,DB00732,Atracurium besylate
,10225075,half-lives,"The half-lives (min) of the alpha, beta and gamma phases (men vs women, medians) were 1.5 vs 2.2, 42 vs 40 and 222 vs 360, respectively.",Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225075/),min,360,208649,DB00732,Atracurium besylate
,10225075,Area under the curve (AUC,"Area under the curve (AUC, min microgram/l) was 39,810 vs 34,905.",Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225075/),[min·μg] / [l],"39,810",208650,DB00732,Atracurium besylate
,10225075,Area under the curve (AUC,"Area under the curve (AUC, min microgram/l) was 39,810 vs 34,905.",Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225075/),[min·μg] / [l],"34,905",208651,DB00732,Atracurium besylate
,1425620,tmax,Ondansetron is rapidly absorbed after oral administration (tmax 1.9 h) with an absolute bioavailability of around 60%.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),h,1.9,210774,DB00732,Atracurium besylate
,1425620,absolute bioavailability,Ondansetron is rapidly absorbed after oral administration (tmax 1.9 h) with an absolute bioavailability of around 60%.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),%,60,210775,DB00732,Atracurium besylate
,1425620,terminal elimination half-life,Its terminal elimination half-life is 3.5 h and it is extensively hepatically metabolized.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),h,3.5,210776,DB00732,Atracurium besylate
,1425620,Plasma clearance,Plasma clearance is 0.38 litre h-1 kg-1 and volume of distribution is 1.8 litre kg-1.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),[l] / [h·kg],0.38,210777,DB00732,Atracurium besylate
,1425620,volume of distribution,Plasma clearance is 0.38 litre h-1 kg-1 and volume of distribution is 1.8 litre kg-1.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),[l] / [kg],1.8,210778,DB00732,Atracurium besylate
,2923767,central volume of distribution,"The central volume of distribution of atracurium was greater in the patients with cirrhosis (104.6 ml kg-1) compared with the controls (69.6 ml kg-1) (P less than 0.05), as was the total volume of distribution (281.8 ml kg-1 and 202.1 ml kg-1, respectively) (P less than 0.05).",Pharmacokinetics of atracurium and laudanosine in patients with hepatic cirrhosis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2923767/),[ml] / [kg],104.6,211270,DB00732,Atracurium besylate
,2923767,central volume of distribution,"The central volume of distribution of atracurium was greater in the patients with cirrhosis (104.6 ml kg-1) compared with the controls (69.6 ml kg-1) (P less than 0.05), as was the total volume of distribution (281.8 ml kg-1 and 202.1 ml kg-1, respectively) (P less than 0.05).",Pharmacokinetics of atracurium and laudanosine in patients with hepatic cirrhosis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2923767/),[ml] / [kg],69.6,211271,DB00732,Atracurium besylate
,2923767,total volume of distribution,"The central volume of distribution of atracurium was greater in the patients with cirrhosis (104.6 ml kg-1) compared with the controls (69.6 ml kg-1) (P less than 0.05), as was the total volume of distribution (281.8 ml kg-1 and 202.1 ml kg-1, respectively) (P less than 0.05).",Pharmacokinetics of atracurium and laudanosine in patients with hepatic cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2923767/),[ml] / [kg],281.8,211272,DB00732,Atracurium besylate
,2923767,total volume of distribution,"The central volume of distribution of atracurium was greater in the patients with cirrhosis (104.6 ml kg-1) compared with the controls (69.6 ml kg-1) (P less than 0.05), as was the total volume of distribution (281.8 ml kg-1 and 202.1 ml kg-1, respectively) (P less than 0.05).",Pharmacokinetics of atracurium and laudanosine in patients with hepatic cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2923767/),[ml] / [kg],202.1,211273,DB00732,Atracurium besylate
,2923767,total volume of distribution,"The total volume of distribution of laudanosine was increased in cirrhotic patients (2.68 litre kg-1) (P less than 0.05), as was its elimination half-life (277 min in cirrhotic individuals; 168 min in controls) (P less than 0.05).",Pharmacokinetics of atracurium and laudanosine in patients with hepatic cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2923767/),[l] / [kg],2.68,211274,DB00732,Atracurium besylate
,2923767,elimination half-life,"The total volume of distribution of laudanosine was increased in cirrhotic patients (2.68 litre kg-1) (P less than 0.05), as was its elimination half-life (277 min in cirrhotic individuals; 168 min in controls) (P less than 0.05).",Pharmacokinetics of atracurium and laudanosine in patients with hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2923767/),min,277,211275,DB00732,Atracurium besylate
,2923767,elimination half-life,"The total volume of distribution of laudanosine was increased in cirrhotic patients (2.68 litre kg-1) (P less than 0.05), as was its elimination half-life (277 min in cirrhotic individuals; 168 min in controls) (P less than 0.05).",Pharmacokinetics of atracurium and laudanosine in patients with hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2923767/),min,168,211276,DB00732,Atracurium besylate
,3606914,plasma elimination half-lives,"Although 2-10% of the dose was recovered in the urine of normal patients as unchanged atracurium, and 3-4% as laudanosine, renal failure produced no significant differences in plasma pharmacokinetics, with mean plasma elimination half-lives of 20 min for atracurium, 234 min for laudanosine and 39 min for quaternary alcohol.","Pharmacokinetics of atracurium and its metabolites in patients with normal renal function, and in patients in renal failure. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3606914/),min,20,212142,DB00732,Atracurium besylate
,3606914,plasma elimination half-lives,"Although 2-10% of the dose was recovered in the urine of normal patients as unchanged atracurium, and 3-4% as laudanosine, renal failure produced no significant differences in plasma pharmacokinetics, with mean plasma elimination half-lives of 20 min for atracurium, 234 min for laudanosine and 39 min for quaternary alcohol.","Pharmacokinetics of atracurium and its metabolites in patients with normal renal function, and in patients in renal failure. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3606914/),min,234,212143,DB00732,Atracurium besylate
,3606914,plasma elimination half-lives,"Although 2-10% of the dose was recovered in the urine of normal patients as unchanged atracurium, and 3-4% as laudanosine, renal failure produced no significant differences in plasma pharmacokinetics, with mean plasma elimination half-lives of 20 min for atracurium, 234 min for laudanosine and 39 min for quaternary alcohol.","Pharmacokinetics of atracurium and its metabolites in patients with normal renal function, and in patients in renal failure. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3606914/),min,39,212144,DB00732,Atracurium besylate
,9989341,total body clearance (CL),"The total body clearance (CL), steady-state Vd and elimination half-life of cisatracurium besilate in patients with normal organ function are approximately 0.28 L/h/kg (4.7 ml/min/kg), 0.145 L/kg and 25 minutes, respectively.",Clinical pharmacokinetics of cisatracurium besilate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989341/),[l] / [h·kg],0.28,216468,DB00732,Atracurium besylate
,9989341,steady-state Vd,"The total body clearance (CL), steady-state Vd and elimination half-life of cisatracurium besilate in patients with normal organ function are approximately 0.28 L/h/kg (4.7 ml/min/kg), 0.145 L/kg and 25 minutes, respectively.",Clinical pharmacokinetics of cisatracurium besilate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989341/),[ml] / [kg·min],4.7,216469,DB00732,Atracurium besylate
,9989341,steady-state Vd,"The total body clearance (CL), steady-state Vd and elimination half-life of cisatracurium besilate in patients with normal organ function are approximately 0.28 L/h/kg (4.7 ml/min/kg), 0.145 L/kg and 25 minutes, respectively.",Clinical pharmacokinetics of cisatracurium besilate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989341/),[l] / [kg],0.145,216470,DB00732,Atracurium besylate
,9989341,elimination half-life,"The total body clearance (CL), steady-state Vd and elimination half-life of cisatracurium besilate in patients with normal organ function are approximately 0.28 L/h/kg (4.7 ml/min/kg), 0.145 L/kg and 25 minutes, respectively.",Clinical pharmacokinetics of cisatracurium besilate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989341/),min,25,216471,DB00732,Atracurium besylate
,8895287,Clearance,"Clearance values (mean +/- SD) were 5.20 +/- 0.86, 4.00 +/- 1.04, 1.20 +/- 0.71, and 0.85 +/- 0.32 mL.min-1.kg-1 for total body clearance, Hofmann clearance, organ clearance, and renal clearance, respectively.",Importance of the organ-independent elimination of cisatracurium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895287/),[ml] / [kg·min],5.20,217685,DB00732,Atracurium besylate
,8895287,Clearance,"Clearance values (mean +/- SD) were 5.20 +/- 0.86, 4.00 +/- 1.04, 1.20 +/- 0.71, and 0.85 +/- 0.32 mL.min-1.kg-1 for total body clearance, Hofmann clearance, organ clearance, and renal clearance, respectively.",Importance of the organ-independent elimination of cisatracurium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895287/),[ml] / [kg·min],4.00,217686,DB00732,Atracurium besylate
,8895287,Clearance,"Clearance values (mean +/- SD) were 5.20 +/- 0.86, 4.00 +/- 1.04, 1.20 +/- 0.71, and 0.85 +/- 0.32 mL.min-1.kg-1 for total body clearance, Hofmann clearance, organ clearance, and renal clearance, respectively.",Importance of the organ-independent elimination of cisatracurium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895287/),[ml] / [kg·min],1.20,217687,DB00732,Atracurium besylate
,8895287,Clearance,"Clearance values (mean +/- SD) were 5.20 +/- 0.86, 4.00 +/- 1.04, 1.20 +/- 0.71, and 0.85 +/- 0.32 mL.min-1.kg-1 for total body clearance, Hofmann clearance, organ clearance, and renal clearance, respectively.",Importance of the organ-independent elimination of cisatracurium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895287/),[ml] / [kg·min],0.85,217688,DB00732,Atracurium besylate
,8895287,total body clearance,"Clearance values (mean +/- SD) were 5.20 +/- 0.86, 4.00 +/- 1.04, 1.20 +/- 0.71, and 0.85 +/- 0.32 mL.min-1.kg-1 for total body clearance, Hofmann clearance, organ clearance, and renal clearance, respectively.",Importance of the organ-independent elimination of cisatracurium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895287/),[ml] / [kg·min],4.00,217689,DB00732,Atracurium besylate
,8895287,total body clearance,"Clearance values (mean +/- SD) were 5.20 +/- 0.86, 4.00 +/- 1.04, 1.20 +/- 0.71, and 0.85 +/- 0.32 mL.min-1.kg-1 for total body clearance, Hofmann clearance, organ clearance, and renal clearance, respectively.",Importance of the organ-independent elimination of cisatracurium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895287/),[ml] / [kg·min],1.20,217690,DB00732,Atracurium besylate
,8895287,total body clearance,"Clearance values (mean +/- SD) were 5.20 +/- 0.86, 4.00 +/- 1.04, 1.20 +/- 0.71, and 0.85 +/- 0.32 mL.min-1.kg-1 for total body clearance, Hofmann clearance, organ clearance, and renal clearance, respectively.",Importance of the organ-independent elimination of cisatracurium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895287/),[ml] / [kg·min],0.85,217691,DB00732,Atracurium besylate
,2898986,ED90,"For vecuronium the ED90 was (mean +/- SE) 0.034 +/- 0.002 (SD), 0.037 +/- 0.003 (CD), and 0.036 +/- 0.003 mg/kg (CDI).",Cumulative dose-response with infusion: a technique to determine neuromuscular blocking potency of atracurium and vecuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898986/),[mg] / [kg],0.034,225767,DB00732,Atracurium besylate
,2898986,ED90,"For vecuronium the ED90 was (mean +/- SE) 0.034 +/- 0.002 (SD), 0.037 +/- 0.003 (CD), and 0.036 +/- 0.003 mg/kg (CDI).",Cumulative dose-response with infusion: a technique to determine neuromuscular blocking potency of atracurium and vecuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898986/),[mg] / [kg],0.037,225768,DB00732,Atracurium besylate
,2898986,ED90,"For vecuronium the ED90 was (mean +/- SE) 0.034 +/- 0.002 (SD), 0.037 +/- 0.003 (CD), and 0.036 +/- 0.003 mg/kg (CDI).",Cumulative dose-response with infusion: a technique to determine neuromuscular blocking potency of atracurium and vecuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898986/),[mg] / [kg],0.036,225769,DB00732,Atracurium besylate
,2898986,ED90,"For atracurium the ED90 was 0.175 +/- 0.009 (SD), 0.206 +/- 0.019 (CD), and 0.179 +/- 0.015 mg/kg (CDI).",Cumulative dose-response with infusion: a technique to determine neuromuscular blocking potency of atracurium and vecuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898986/),[mg] / [kg],0.175,225770,DB00732,Atracurium besylate
,2898986,ED90,"For atracurium the ED90 was 0.175 +/- 0.009 (SD), 0.206 +/- 0.019 (CD), and 0.179 +/- 0.015 mg/kg (CDI).",Cumulative dose-response with infusion: a technique to determine neuromuscular blocking potency of atracurium and vecuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898986/),[mg] / [kg],0.206,225771,DB00732,Atracurium besylate
,2898986,ED90,"For atracurium the ED90 was 0.175 +/- 0.009 (SD), 0.206 +/- 0.019 (CD), and 0.179 +/- 0.015 mg/kg (CDI).",Cumulative dose-response with infusion: a technique to determine neuromuscular blocking potency of atracurium and vecuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898986/),[mg] / [kg],0.179,225772,DB00732,Atracurium besylate
,24631811,detection limit,"The assay was linear from 50 to 2800ngmL(-1), with a detection limit of 12ngmL(-1).",High-performance liquid chromatography assay with programmed flow elution for cisatracurium in human plasma: application to pharmacokinetics in infants and children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24631811/),1/[ngml],12,232389,DB00732,Atracurium besylate
,24631811,recoveries,The mean recoveries were in the range of 92.1-100.4%.,High-performance liquid chromatography assay with programmed flow elution for cisatracurium in human plasma: application to pharmacokinetics in infants and children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24631811/),%,92.1-100.4,232390,DB00732,Atracurium besylate
less,24631811,total HPLC run time,The total HPLC run time was less than 10min.,High-performance liquid chromatography assay with programmed flow elution for cisatracurium in human plasma: application to pharmacokinetics in infants and children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24631811/),min,10,232391,DB00732,Atracurium besylate
,8106686,steady state clearance,"Atracurium mean steady state clearance was 8.6 ml/min/kg, and train-of-four recovery ratio to 75% took 63 min (range 32-108).",Atracurium infusions in patients with fulminant hepatic failure awaiting liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106686/),[ml] / [kg·min],8.6,232640,DB00732,Atracurium besylate
,8106686,train-of-four recovery ratio,"Atracurium mean steady state clearance was 8.6 ml/min/kg, and train-of-four recovery ratio to 75% took 63 min (range 32-108).",Atracurium infusions in patients with fulminant hepatic failure awaiting liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106686/),,63,232641,DB00732,Atracurium besylate
,8106686,half-life,Laudanosine clearance was markedly reduced in the non-survivors; the half-life was 38.5 hrs compared with 5.3 h in the 4 patients who underwent successful transplantation.,Atracurium infusions in patients with fulminant hepatic failure awaiting liver transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106686/),h,38.5,232642,DB00732,Atracurium besylate
,8106686,half-life,Laudanosine clearance was markedly reduced in the non-survivors; the half-life was 38.5 hrs compared with 5.3 h in the 4 patients who underwent successful transplantation.,Atracurium infusions in patients with fulminant hepatic failure awaiting liver transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106686/),h,5.3,232643,DB00732,Atracurium besylate
,2936284,elimination half-life,Spontaneous degradation of atracurium in plasma is the major route of elimination in man and contributes to a short elimination half-life (approximatively 20 min).,[Metabolism and pharmacokinetics of atracurium]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2936284/),min,20,233088,DB00732,Atracurium besylate
,8688259,Volume of distribution at steady state,"Volume of distribution at steady state was 195 (SD 38) ml kg-1 in liver transplant patients and 161 (23) ml kg-1 in control patients (P < 0.05), plasma clearance was 6.6 (1.1) ml kg-1 min-1 in liver transplant patients and 5.7 (0.8) ml kg-1 min-1 in control patients (P < 0.05), but elimination half-lives were similar: 24.4 (2.9) min in liver transplant patients vs 23.5 (3.5) min in control patients (ns).",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),[ml] / [kg],195,235035,DB00732,Atracurium besylate
,8688259,Volume of distribution at steady state,"Volume of distribution at steady state was 195 (SD 38) ml kg-1 in liver transplant patients and 161 (23) ml kg-1 in control patients (P < 0.05), plasma clearance was 6.6 (1.1) ml kg-1 min-1 in liver transplant patients and 5.7 (0.8) ml kg-1 min-1 in control patients (P < 0.05), but elimination half-lives were similar: 24.4 (2.9) min in liver transplant patients vs 23.5 (3.5) min in control patients (ns).",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),[ml] / [kg],161,235036,DB00732,Atracurium besylate
,8688259,plasma clearance,"Volume of distribution at steady state was 195 (SD 38) ml kg-1 in liver transplant patients and 161 (23) ml kg-1 in control patients (P < 0.05), plasma clearance was 6.6 (1.1) ml kg-1 min-1 in liver transplant patients and 5.7 (0.8) ml kg-1 min-1 in control patients (P < 0.05), but elimination half-lives were similar: 24.4 (2.9) min in liver transplant patients vs 23.5 (3.5) min in control patients (ns).",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),[ml] / [kg·min],6.6,235037,DB00732,Atracurium besylate
,8688259,plasma clearance,"Volume of distribution at steady state was 195 (SD 38) ml kg-1 in liver transplant patients and 161 (23) ml kg-1 in control patients (P < 0.05), plasma clearance was 6.6 (1.1) ml kg-1 min-1 in liver transplant patients and 5.7 (0.8) ml kg-1 min-1 in control patients (P < 0.05), but elimination half-lives were similar: 24.4 (2.9) min in liver transplant patients vs 23.5 (3.5) min in control patients (ns).",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),[ml] / [kg·min],5.7,235038,DB00732,Atracurium besylate
,8688259,elimination half-lives,"Volume of distribution at steady state was 195 (SD 38) ml kg-1 in liver transplant patients and 161 (23) ml kg-1 in control patients (P < 0.05), plasma clearance was 6.6 (1.1) ml kg-1 min-1 in liver transplant patients and 5.7 (0.8) ml kg-1 min-1 in control patients (P < 0.05), but elimination half-lives were similar: 24.4 (2.9) min in liver transplant patients vs 23.5 (3.5) min in control patients (ns).",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),min,24.4,235039,DB00732,Atracurium besylate
,8688259,elimination half-lives,"Volume of distribution at steady state was 195 (SD 38) ml kg-1 in liver transplant patients and 161 (23) ml kg-1 in control patients (P < 0.05), plasma clearance was 6.6 (1.1) ml kg-1 min-1 in liver transplant patients and 5.7 (0.8) ml kg-1 min-1 in control patients (P < 0.05), but elimination half-lives were similar: 24.4 (2.9) min in liver transplant patients vs 23.5 (3.5) min in control patients (ns).",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),min,23.5,235040,DB00732,Atracurium besylate
,8688259,time to maximum block,"The time to maximum block was 2.4 (0.8) min in liver transplant patients compared with 3.3 (1.0) min in control patients (P < 0.05), but the clinical effective duration of action (time to 25% recovery) was similar: 53.5 (11.9) min in liver transplant patients compared with 46.9 (6.9) min in control patients (ns).",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),min,2.4,235041,DB00732,Atracurium besylate
,8688259,time to maximum block,"The time to maximum block was 2.4 (0.8) min in liver transplant patients compared with 3.3 (1.0) min in control patients (P < 0.05), but the clinical effective duration of action (time to 25% recovery) was similar: 53.5 (11.9) min in liver transplant patients compared with 46.9 (6.9) min in control patients (ns).",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),min,3.3,235042,DB00732,Atracurium besylate
,8688259,clinical effective duration of action (,"The time to maximum block was 2.4 (0.8) min in liver transplant patients compared with 3.3 (1.0) min in control patients (P < 0.05), but the clinical effective duration of action (time to 25% recovery) was similar: 53.5 (11.9) min in liver transplant patients compared with 46.9 (6.9) min in control patients (ns).",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),min,53.5,235043,DB00732,Atracurium besylate
,8688259,time to 25% recovery),"The time to maximum block was 2.4 (0.8) min in liver transplant patients compared with 3.3 (1.0) min in control patients (P < 0.05), but the clinical effective duration of action (time to 25% recovery) was similar: 53.5 (11.9) min in liver transplant patients compared with 46.9 (6.9) min in control patients (ns).",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),min,53.5,235044,DB00732,Atracurium besylate
,8688259,time to 25% recovery),"The time to maximum block was 2.4 (0.8) min in liver transplant patients compared with 3.3 (1.0) min in control patients (P < 0.05), but the clinical effective duration of action (time to 25% recovery) was similar: 53.5 (11.9) min in liver transplant patients compared with 46.9 (6.9) min in control patients (ns).",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),min,46.9,235045,DB00732,Atracurium besylate
,8688259,recovery index,The recovery index (25-75% recovery) was also similar in both groups: 15.4 (4.2) min in liver transplant patients and 12.8 (1.9) min in control patients (ns).,Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),min,15.4,235046,DB00732,Atracurium besylate
,8688259,recovery index,The recovery index (25-75% recovery) was also similar in both groups: 15.4 (4.2) min in liver transplant patients and 12.8 (1.9) min in control patients (ns).,Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),min,12.8,235047,DB00732,Atracurium besylate
,8688259,peak laudanosine concentrations,"After cisatracurium, peak laudanosine concentrations were 16 (5) and 21 (5) ng ml-1 in liver transplant and control patients, respectively.",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),[ng] / [ml],16,235048,DB00732,Atracurium besylate
,8688259,peak laudanosine concentrations,"After cisatracurium, peak laudanosine concentrations were 16 (5) and 21 (5) ng ml-1 in liver transplant and control patients, respectively.",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),[ng] / [ml],21,235049,DB00732,Atracurium besylate
,10223167,clearance,It has a low clearance (0.16 L/h/kg) and long elimination half-life (120 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.16,240354,DB00732,Atracurium besylate
,10223167,elimination half-life,It has a low clearance (0.16 L/h/kg) and long elimination half-life (120 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,120,240355,DB00732,Atracurium besylate
,10223167,clearance,"Its clearance (0.27 L/h/kg) is intermediate between those of pipecuronium and rapacuronium, but its elimination half-life is long (83 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.27,240356,DB00732,Atracurium besylate
,10223167,elimination half-life,"Its clearance (0.27 L/h/kg) is intermediate between those of pipecuronium and rapacuronium, but its elimination half-life is long (83 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,83,240357,DB00732,Atracurium besylate
,10223167,clearance,It has a high clearance (0.59 L/h/kg) but a long elimination half-life (112 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.59,240358,DB00732,Atracurium besylate
,10223167,elimination half-life,It has a high clearance (0.59 L/h/kg) but a long elimination half-life (112 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,112,240359,DB00732,Atracurium besylate
,10223167,clearance,"In adults, it has a low clearance (0.15 L/h/kg) and long elimination half-life (87 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.15,240360,DB00732,Atracurium besylate
,10223167,elimination half-life,"In adults, it has a low clearance (0.15 L/h/kg) and long elimination half-life (87 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,87,240361,DB00732,Atracurium besylate
,10223167,clearance,The 2 active isomers (cis-trans and trans-trans) have a high clearance (4.74 L/h/kg) and very short elimination half-lives (approximately 2 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],4.74,240362,DB00732,Atracurium besylate
,10223167,elimination half-lives,The 2 active isomers (cis-trans and trans-trans) have a high clearance (4.74 L/h/kg) and very short elimination half-lives (approximately 2 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,2,240363,DB00732,Atracurium besylate
,10223167,clearance,Cisatracurium has an intermediate clearance (0.3 L/h/kg) and short elimination half-life (26 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.3,240364,DB00732,Atracurium besylate
,10223167,elimination half-life,Cisatracurium has an intermediate clearance (0.3 L/h/kg) and short elimination half-life (26 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,26,240365,DB00732,Atracurium besylate
,2875680,5-25% recovery time,"When the dose of vecuronium was increased from 40 to 80 micrograms/kg, 5-25% recovery time increased from 6.0 +/- 2.5 min to 8.8 +/- 4.0 min (mean +/- SD) and 25-75% recovery time increased from 8.7 +/- 4.3 min to 12.6 +/- 4.4 min.",A pharmacokinetic explanation for increasing recovery time following larger or repeated doses of nondepolarizing muscle relaxants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875680/),min,6.0,242933,DB00732,Atracurium besylate
,2875680,5-25% recovery time,"When the dose of vecuronium was increased from 40 to 80 micrograms/kg, 5-25% recovery time increased from 6.0 +/- 2.5 min to 8.8 +/- 4.0 min (mean +/- SD) and 25-75% recovery time increased from 8.7 +/- 4.3 min to 12.6 +/- 4.4 min.",A pharmacokinetic explanation for increasing recovery time following larger or repeated doses of nondepolarizing muscle relaxants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875680/),min,8.8,242934,DB00732,Atracurium besylate
,2875680,25-75% recovery time,"When the dose of vecuronium was increased from 40 to 80 micrograms/kg, 5-25% recovery time increased from 6.0 +/- 2.5 min to 8.8 +/- 4.0 min (mean +/- SD) and 25-75% recovery time increased from 8.7 +/- 4.3 min to 12.6 +/- 4.4 min.",A pharmacokinetic explanation for increasing recovery time following larger or repeated doses of nondepolarizing muscle relaxants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875680/),min,8.7,242935,DB00732,Atracurium besylate
,2875680,25-75% recovery time,"When the dose of vecuronium was increased from 40 to 80 micrograms/kg, 5-25% recovery time increased from 6.0 +/- 2.5 min to 8.8 +/- 4.0 min (mean +/- SD) and 25-75% recovery time increased from 8.7 +/- 4.3 min to 12.6 +/- 4.4 min.",A pharmacokinetic explanation for increasing recovery time following larger or repeated doses of nondepolarizing muscle relaxants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875680/),min,12.6,242936,DB00732,Atracurium besylate
,22584638,Time of onset,"Time of onset was significantly shorter for rocuronium than cisatracurium for the adult and elderly groups (P = 0.000), but the variability of cisatracurium was significantly greater compared with rocuronium for the same age groups (93.25 vs 37.01 s in the adult group and 64.56 vs 33.75 s in the elderly group; P = 0.000).",Comparison of the variability of the onset and recovery from neuromuscular blockade with cisatracurium versus rocuronium in elderly patients under total intravenous anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22584638/),s,93.25,250592,DB00732,Atracurium besylate
,22584638,Time of onset,"Time of onset was significantly shorter for rocuronium than cisatracurium for the adult and elderly groups (P = 0.000), but the variability of cisatracurium was significantly greater compared with rocuronium for the same age groups (93.25 vs 37.01 s in the adult group and 64.56 vs 33.75 s in the elderly group; P = 0.000).",Comparison of the variability of the onset and recovery from neuromuscular blockade with cisatracurium versus rocuronium in elderly patients under total intravenous anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22584638/),s,37.01,250593,DB00732,Atracurium besylate
,22584638,Time of onset,"Time of onset was significantly shorter for rocuronium than cisatracurium for the adult and elderly groups (P = 0.000), but the variability of cisatracurium was significantly greater compared with rocuronium for the same age groups (93.25 vs 37.01 s in the adult group and 64.56 vs 33.75 s in the elderly group; P = 0.000).",Comparison of the variability of the onset and recovery from neuromuscular blockade with cisatracurium versus rocuronium in elderly patients under total intravenous anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22584638/),s,64.56,250594,DB00732,Atracurium besylate
,22584638,Time of onset,"Time of onset was significantly shorter for rocuronium than cisatracurium for the adult and elderly groups (P = 0.000), but the variability of cisatracurium was significantly greater compared with rocuronium for the same age groups (93.25 vs 37.01 s in the adult group and 64.56 vs 33.75 s in the elderly group; P = 0.000).",Comparison of the variability of the onset and recovery from neuromuscular blockade with cisatracurium versus rocuronium in elderly patients under total intravenous anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22584638/),s,33.75,250595,DB00732,Atracurium besylate
,3729058,elimination half-life,Three-compartment modeling of plasma laudanosine concentrations yielded an elimination half-life for laudanosine of 113 +/- 24 min (mean +/- SD) and a clearance of 25 +/- 8 ml . kg-1 . min-1.,Pharmacology of laudanosine in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3729058/),min,113,250680,DB00732,Atracurium besylate
,3729058,clearance,Three-compartment modeling of plasma laudanosine concentrations yielded an elimination half-life for laudanosine of 113 +/- 24 min (mean +/- SD) and a clearance of 25 +/- 8 ml . kg-1 . min-1.,Pharmacology of laudanosine in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3729058/),[ml] / [kg·min],25,250681,DB00732,Atracurium besylate
,3729058,PaCO2,"After a 6-h sampling period, dogs were hyperventilated with halothane (FIO2 = 0.2) to a PaCO2 of 26-28 mmHg.",Pharmacology of laudanosine in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3729058/),mmh,26-28,250682,DB00732,Atracurium besylate
,26470914,onset time,"The onset time (i.e., the time to maximal neuromuscular block) was prolonged from 2.2 minutes to 5.0 minutes.",Altered Cisatracurium Pharmacokinetics and Pharmacodynamics in Patients with Congenital Heart Defects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26470914/),min,2.2,264092,DB00732,Atracurium besylate
,26470914,onset time,"The onset time (i.e., the time to maximal neuromuscular block) was prolonged from 2.2 minutes to 5.0 minutes.",Altered Cisatracurium Pharmacokinetics and Pharmacodynamics in Patients with Congenital Heart Defects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26470914/),min,5.0,264093,DB00732,Atracurium besylate
,26470914,time to maximal neuromuscular block,"The onset time (i.e., the time to maximal neuromuscular block) was prolonged from 2.2 minutes to 5.0 minutes.",Altered Cisatracurium Pharmacokinetics and Pharmacodynamics in Patients with Congenital Heart Defects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26470914/),min,2.2,264094,DB00732,Atracurium besylate
,26470914,time to maximal neuromuscular block,"The onset time (i.e., the time to maximal neuromuscular block) was prolonged from 2.2 minutes to 5.0 minutes.",Altered Cisatracurium Pharmacokinetics and Pharmacodynamics in Patients with Congenital Heart Defects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26470914/),min,5.0,264095,DB00732,Atracurium besylate
,7712666,half-lives of uptake into,"From the depression of the first twitch after three consecutive doses in eight patients, the half-lives of uptake into and elimination from the effect compartment were 2.1 +/- 0.2 minutes (mean +/- SEM) and 25.8 +/- 2.3 minutes (n = 8).",Pharmacokinetic analysis of the time course of effect of atracurium. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712666/),min,2.1,264384,DB00732,Atracurium besylate
,7712666,elimination from the effect compartment,"From the depression of the first twitch after three consecutive doses in eight patients, the half-lives of uptake into and elimination from the effect compartment were 2.1 +/- 0.2 minutes (mean +/- SEM) and 25.8 +/- 2.3 minutes (n = 8).",Pharmacokinetic analysis of the time course of effect of atracurium. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712666/),min,25.8,264385,DB00732,Atracurium besylate
,7712666,ED50,"The doses producing 50% and 95% depression of the first twitch (ED50 and ED95) were 168 +/- 15 and 280 +/- 25 micrograms/kg, respectively, with a Hill coefficient of 6.1 +/- 0.5.",Pharmacokinetic analysis of the time course of effect of atracurium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712666/),[μg] / [kg],168,264386,DB00732,Atracurium besylate
,7712666,Hill coefficient,"The doses producing 50% and 95% depression of the first twitch (ED50 and ED95) were 168 +/- 15 and 280 +/- 25 micrograms/kg, respectively, with a Hill coefficient of 6.1 +/- 0.5.",Pharmacokinetic analysis of the time course of effect of atracurium. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712666/),,6.1,264387,DB00732,Atracurium besylate
,3755306,rate constant,The values for this rate constant ranged from 0.0193 to 0.0238 per min.,Elimination of atracurium in humans: contribution of Hofmann elimination and ester hydrolysis versus organ-based elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3755306/),1/[min],0.0193 to 0.0238,266421,DB00732,Atracurium besylate
,3755306,Cl total,"When these values were applied to the pharmacokinetic model, Cl total, Cl organ, and Cl nonorgan were 4.8 +/- 1.1, 3.0 +/- 0.9, and 1.9 +/- 0.6 ml . kg-1 . min-1, respectively.",Elimination of atracurium in humans: contribution of Hofmann elimination and ester hydrolysis versus organ-based elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3755306/),[ml] / [kg·min],4.8,266422,DB00732,Atracurium besylate
,3755306,Cl organ,"When these values were applied to the pharmacokinetic model, Cl total, Cl organ, and Cl nonorgan were 4.8 +/- 1.1, 3.0 +/- 0.9, and 1.9 +/- 0.6 ml . kg-1 . min-1, respectively.",Elimination of atracurium in humans: contribution of Hofmann elimination and ester hydrolysis versus organ-based elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3755306/),[ml] / [kg·min],3.0,266423,DB00732,Atracurium besylate
,3755306,Cl nonorgan,"When these values were applied to the pharmacokinetic model, Cl total, Cl organ, and Cl nonorgan were 4.8 +/- 1.1, 3.0 +/- 0.9, and 1.9 +/- 0.6 ml . kg-1 . min-1, respectively.",Elimination of atracurium in humans: contribution of Hofmann elimination and ester hydrolysis versus organ-based elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3755306/),[ml] / [kg·min],1.9,266424,DB00732,Atracurium besylate
,3780694,protein binding,The protein binding of laudanosine was 80%.,Convulsive effects and pharmacokinetics of laudanosine in the rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780694/),%,80,270361,DB00732,Atracurium besylate
,7618663,recovery times from maximum block to 50% recovery,"In these experiments, the recovery times from maximum block to 50% recovery of control twitch height were significantly longer with mivacurium than with atracurium (mean 25.2(SD 4.7) versus 22.6(3.1) min, p < 0.01).",Discrepancy of recovery times related to potency between atracurium and mivacurium simultaneously administered in isolated forearms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7618663/),min,25.2,271654,DB00732,Atracurium besylate
,7618663,recovery times from maximum block to 50% recovery,"In these experiments, the recovery times from maximum block to 50% recovery of control twitch height were significantly longer with mivacurium than with atracurium (mean 25.2(SD 4.7) versus 22.6(3.1) min, p < 0.01).",Discrepancy of recovery times related to potency between atracurium and mivacurium simultaneously administered in isolated forearms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7618663/),min,22.6,271655,DB00732,Atracurium besylate
,31969113,onset time to maximal neuromuscular block,"The onset time to maximal neuromuscular block was prolonged from 2.07 ± 0.08 min to 4.03 ± 0.14 min, which indicated that the PD responses to cisatracurium were significantly delayed in the AR group (P < 0.05) compared to the control group.",Abnormal cisatracurium pharmacodynamics and pharmacokinetics among patients with severe aortic regurgitation during anesthetic induction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969113/),min,2.07,273947,DB00732,Atracurium besylate
,31969113,onset time to maximal neuromuscular block,"The onset time to maximal neuromuscular block was prolonged from 2.07 ± 0.08 min to 4.03 ± 0.14 min, which indicated that the PD responses to cisatracurium were significantly delayed in the AR group (P < 0.05) compared to the control group.",Abnormal cisatracurium pharmacodynamics and pharmacokinetics among patients with severe aortic regurgitation during anesthetic induction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969113/),min,4.03,273948,DB00732,Atracurium besylate
,31969113,K21,"A conventional two-compartment PK model showed a higher plasma concentration of cisatracurium among the AR group with markedly reduced intercompartment transfer rate (K12 = 0.19 ± 0.02 and K21 = 0.11 ± 0.01 in the AR group vs. K12=0.26 ± 0.01 and K21 = 0.19 ± 0.01 in the control group, P < 0.01) compared to the control group.",Abnormal cisatracurium pharmacodynamics and pharmacokinetics among patients with severe aortic regurgitation during anesthetic induction. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969113/),,0.11,273949,DB00732,Atracurium besylate
,31969113,K12,"A conventional two-compartment PK model showed a higher plasma concentration of cisatracurium among the AR group with markedly reduced intercompartment transfer rate (K12 = 0.19 ± 0.02 and K21 = 0.11 ± 0.01 in the AR group vs. K12=0.26 ± 0.01 and K21 = 0.19 ± 0.01 in the control group, P < 0.01) compared to the control group.",Abnormal cisatracurium pharmacodynamics and pharmacokinetics among patients with severe aortic regurgitation during anesthetic induction. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969113/),,0.26,273950,DB00732,Atracurium besylate
,31969113,K21,"A conventional two-compartment PK model showed a higher plasma concentration of cisatracurium among the AR group with markedly reduced intercompartment transfer rate (K12 = 0.19 ± 0.02 and K21 = 0.11 ± 0.01 in the AR group vs. K12=0.26 ± 0.01 and K21 = 0.19 ± 0.01 in the control group, P < 0.01) compared to the control group.",Abnormal cisatracurium pharmacodynamics and pharmacokinetics among patients with severe aortic regurgitation during anesthetic induction. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969113/),,0.19,273951,DB00732,Atracurium besylate
